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AIMS OF THE STUDY 
 
1. TO STUDY THE SURVIVAL OUTCOMES OF THE PATIENTS UNDERGOING 
LIMB SALVAGE SURGERY IN PROXIMAL TIBIAL TUMOURS WITH 
CUSTOM MADE MEGAPROSTHESIS. 
 
2. TO COMPARE THE QUALITY OF LIFE ASSESSMENT BETWEEN GROUPS 
UNDERGOING EXTENSOR MECHANISM RECONSTRUCTION WITH OR 
WITHOUT A PROLENE MESH. 
 
3. TO STUDY THE EARLY AND LATE COMPLICATIONS. 
 
 
4. TO STUDY THE PROSTHESIS SURVIVAL TIME AND THE FACTORS 
AFFECTING PROSTHESIS SURVIVAL. 
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  INTRODUCTION 
“Walking is man’s best medicine”     - Hippocrates 
Bony sarcomas arising from the proximal end of the tibia constitute the second most 
common site of occurrenceafter the distal end of the femur.  However this area is a difficult 
site to perform a safe limb sparing resection in which function is preserved due to anatomical 
constraints and also surgical technique. Historically amputation had been the treatment for 
bony sarcomas. The use of effective chemotherapeutic regimen,  modern imaging technology 
and advances in surgical techniques has broadened the horizon and scope of limb salvage 
surgery in this site. The primary difficulty in doing a limb salvage surgery for sarcoma of the 
proximal tibia is due to the local anatomy. A difficult surgical approach, intimate relationship 
to the neurovascular structures, inadequate soft tissue coverage are few of the challenges 
surgeons face during procedures at this site. Another important factor is the need to 
reconstruct the extensor mechanism of the knee joint. Many surgical techniques and 
reconstruction mechanisms have been described for the tumours at this site and have 
provided satisfactory survival and functional outcomes. 
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REVIEW OF LITERATURE 
HISTORY OF BONE SARCOMAS 
Osteosarcoma as a disease was recognised since ancient times. An English surgeon 
named John Abernathy coined the term “sarcoma” in 1804 which was derived from Greek 
roots and means “fleshy excrescence.”1  Alexis Boyer a French surgeon ( personal surgeon to 
Napoleon ) recognised that sarcomas arising in the bone are a distinct entity from other bony 
lesion and is credited with using the term osteosarcomas for the first time in 1805.
1 
The gross pathological appearance of this tumour was accurately described by 
Guillaume Dupuytren in 1847. He the described the appearance as the following: 
"Osteosarcoma, which is a true cancerous degeneration of bone, manifests itself in the 
form of a white or reddish mass, lardaceous and firm at an early stage of the disease; but 
presenting at a later period, points of softening, cerebriform matter, extravasating blood, and 
white or straw coloured fluid of a viscid consistence in its interior.”1 
As there was limited experience to guide the surgeons of that time a Registry of Bone 
Sarcoma was created in 1921 under the auspices of the American College of Surgeons, by 
Ernest Amory Codman (along with James Ewing and Joseph Bloodgood).
2 
Great advances were made in the field of pathology of bone tumours in the mid-
1900s. Henry Jaffe and Louis Lichtenstein published textbooks on bone pathology that 
established many of the important pathological criteria which are used to diagnose the 
commonly seen bone tumours. 
Dr Norman Jaffe and few others popularised the use of chemotherapeutic drugs for 
osteosarcomas in the 1970s and early 1980s.
3 
Most commonly Adriamycin and methotrexate 
were used. At MSKCC Rosen found out that these chemotherapeutic drugs useful both 
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preoperatively as well as postoperatively while studying the patients who were awaiting the 
custom made prosthesis for their surgery.
4 
William F. Enneking is an eminent name in the field of orthopaedic oncology. He 
introduced the a surgical staging system for bone sarcomas and trained many orthopaedic 
oncology fellows, several research papers have been published by him and actively 
conducted continuing medical education course on bone tumours. 
The staging system described by Enneking et al is based on GTM: grade(G), 
location(T), lymph node involvement and metastasis (M). The staging system is as follows: 
 
Stage IA (G1 T1 M0): Low grade intra-compartmental lesion, without metastasis. 
Stage IB (G1 T2 M0): Low grade extra-compartmental lesion, without metastasis. 
Stage IIA (G2 T1 M0): High grade intra-compartmental lesion, without metastasis. 
Stage IIB (G2 T2 M0): High grade extra-compartmental lesion, without metastasis. 
Stage IIIA (G1 or G2 T1 M1): Any grade intra-compartmental lesion with regional nodal or 
distant metastasis. 
Stage IIIB (G1 or G2 T2 M1): Any grade extra-compartmental lesion with metastasis. 
 
 
 
 
 
 
 
 
 
5 
 
HISTORY OF LIMB SALVAGE SURGERY AND CUSTOM MADE PROSTHESIS 
Amputation was the traditional treatment for osteosarcomsEiselberg in 1897 and 
Klapp in 1900 are probably the first people to perform limb salvage surgery and used bone 
grafts to reconstruct the defects.  Lexter introduced the concept of using allografts in tumour 
surgeries.  The concept of resection arthrodesis was introduced by Phemister for lesions 
above the knee and this technique was further refined by Merle D‟ Aubigne and Dejouany.  
Till the 1960s the limb salvage surgery for bone tumours was restricted to benign and 
lower grade tumours. The development of newer reconstructive techniques including internal 
fixation led to the cautious use of limb salvage surgeries in high grade sarcomas.
6
 
In the 1970s the improvements in imaging techniques ( CT scans ) and use of 
effective chemotherapeutic agents led to great advances in the limb salvage surgeries. 
Musculoskeletal Tumour Society (MSTS) was formed in this decade and met for the first 
time in 1979.
6 
In the 1980s there were tremendous advances in orthopaedic oncology. Surgical 
staging system was developed, surgical margins were defined and International Society on 
Limb Salvage (ISOLS) was formed in 1981.  In the ISOLS meet in 1981 they reported a local 
recurrence rate of 18% and reconstructive failures in 15% and the second symposium held in 
1983 in Vienna reported a local recurrence of 11% and reconstructive failures in 10%. The 
third meet held at Orlando reported a further declinein local recurrence (7%) and 
reconstructive failures (5%).
6 
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PROXIMAL TIBIAL OSTEOSARCOMAS 
Over the past 25 years the concept of limb salvage surgery has grown dramatically. 
Adriamycin- and methotrexate based chemotherapy which was introduced in the 1970s at 
Memorial–Sloan Kettering, New York University, and the Children‟s Hospital of 
Philadelphia made a huge impact in the prognosis and management of patients with bone 
sarcomas. Pioneering work by surgeons such as Ralph Marcove, Kenneth Francis, andHugh 
Watts led to the development of the techniques of limb salvage surgery.  
 Nowadays 90–95% of patients with extremitysarcomas who are being treated 
at centres specializingin musculoskeletal oncology are undergoing limb salvage surgery 
successfully. Advances in several fields have brought about this dramatic change. The 
following advances are the important ones among them. 
1. Tumour biology and natural history are better understood.  
2. There exists an effective induction chemotherapy with which even borderline cases can be 
salvaged.  
3. Advancements in surgical techniques have brought about better functional outcomes. Even 
limbs in which the vessels have been involved can be salvaged with vascular grafts. 
4. Better appreciation of biomechanics of the musculoskeletal system has led to better 
designing of the prosthesis and better outcomes functionally.  
7 
 
5.  Novel materials are being used in the manufacturing of prosthesis due to advances in 
material engineering.  
6.  Prosthesis has been developed for virtually every site in the extremity which has been 
affected by bony tumours.
10
 
 However when considering a limb salvage surgery instead of an amputation certain 
factors have to be kept in mind 
1) There should not be an increased risk to the patient‟s life because of the procedure.  
2) Functional result should be better. 
3) Complication rate must be acceptably low.  
4) Patient and attenders must be fully informed about the procedure, the complications and 
the rehabilitation process.
9
 
 
Several technical issues have to be addressed for the successful outcome of a limb salvage 
surgery.  
a. Key neurovascular structures must be identified and preserved. 
b. Oncological safe margins must be obtained, and preservation of a limb must never 
take priority over thesurvival of the patient. Meticulous surgical technique is 
necessary for achieving a safe margin 
c. Reconstruction of the axial skeleton must be done with appropriate prosthesis 
d. Restoration of good soft-tissue cover isnecessary for good prosthesis function and 
life.
10
 
 
Patient selection for limb salvage surgeries 
The introduction of effective chemotherapeutic agents for osteosarcoma has expanded 
the scope of limb salvage surgery. But the increased survival rates have now placed greater 
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importance on the functional outcome and the prosthesis survival. Today reconstruction has 
to take into account the functional, cosmetic and also the psychological needs of the patient.
10
 
The most important factors that decide about decision to perform a limb salvage 
surgery successfully are location of the tumour and the involvement of neurovascular 
structures.  
Picci et al. listed 6 anatomical sites where providing sufficient margins for resection is 
a problem.
11
 
1. Popliteal space. 
2. Joint structures. 
3. Medullary canal. 
4. Soft tissue involvement. 
5. Venous thrombi. 
6. Sites of periosteal reaction. 
However with the use of preoperative chemotherapy many patients who are 
borderline candidates for limb salvage surgery upfront may ultimately become candidates for 
limb salvage surgery. The patient should always be re-evaluated after the completionof the 
chemotherapy and only then the final decision to proceed or not to proceed with the limb 
salvage surgery must be taken.  
The proximal tibial bony sarcomas are a challenging group of tumours in the 
perspective of limb salvage. Surgical approach to these tumours is difficult, anatomical 
constraints and inadequate soft tissue cover make providing adequate margins and 
reconstruction at this site challenging. Providing a good functional outcome with 
reconstruction of the extensor mechanism is an important aspect of the reconstruction and 
rehabilitation of this subgroup of patient.   
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ANATOMICAL CONSIDERATIONS IN THE PROXIMAL TIBIAL SARCOMAS
12 
A. Popliteal artery trifurcation. 
Thepopliteal trifurcation is actually a combination of two successive bifurcations. 
First the anterior tibial arises from the popliteal artery at the lower border of the popliteus.The 
popliteal artery continues as the tibioperoneal trunk and then bifurcates into peroneal artery 
and the posterior tibial artery. It may be necessary to ligate the anterior tibial artery to provide 
adequate soft tissue clearance. The popliteus muscle on the posterior surface of the tibia 
provides a barrier to the posterior soft tissue extension from the tibia and protects the 
popliteal artery and its branches.
12
 
 
B. Tibiofibular joint. 
Tumours of the proximal tibia have a high incidence of involvement of the tissues of 
the proximal tibiofibular joint. An en-bloc resection of this joint is usually necessary to 
provide adequate margin, especially for high grade sarcomas.
12 
 
C. Knee joint. 
The knee joint is not usually directly involved by the tumours of the proximal tibia. 
This can occur if there has been a fracture or contamination due to a ill performed biopsy 
procedure. Hemarthrosis suggests intra-articular extension of the disease. MRI of the knee 
joint provides the most accurate assessment of the knee joint involvement. If knee joint 
involvement is suspected an extra-articular resection has to be planned.
12 
 
D. Extensor mechanism. 
The reconstruction of the extensor mechanism by reattaching the patellar tendon is a 
challenging aspect of limb salvage surgery of the proximal tibia. Reconstruction of this 
10 
 
mechanism is necessary for a good function of the lower limb. Various mechanisms of 
reconstruction of the extensor mechanisms have been tried over the years and these will be 
described later.
12 
 
E. Subcutaneous location and less soft tissue coverage.  
The medial aspect of the entire length of the tibia occupies the subcutaneous location. This 
leaves the reconstructed prosthesis in a subcutaneous location and is an important source of 
infection and prosthesis failure. The use of the medial gastrocnemius muscle has led to 
provision of adequate soft tissue cover for reconstruction and reduced the incidence of 
infection, flap necrosis, and secondary infection.
12
The musculotendinous insertion of the 
medial gastrocnemius was divided and it was rotated to cover the prosthesis and the 
reconstructed extensor mechanism and sutured to the underlying patellar tendon and the 
quadriceps muscle.
17
 
 
 
Various options exist for the reconstruction of these tumours  
 
1. Resection arthrodesis. 
Prior to the 1970s this was the main method of reconstruction. It had the advantages 
of providing good stability, and a durable reconstruction. But as there was no movement at 
the reconstructed limb as the knee joint was resected and as the result the quality of life was 
poor. Nowadays due to adequate preservation of soft tissue as a result of effective 
chemotherapy and use of medial gastrocnemius for soft tissue cover this method is rarely 
followed.
10 
 
11 
 
 
Fig 1. Intraoperative photograph of resection arthrodesis using dual fibular reconstruction 
with an intramedullary rod fixation following resection of the distal femur, a technique 
popularized by Dr William F. Enneking during 1970s.
10 
 
 
2. Van Nesrotationoplasty. 
This procedure was first described by Borggreve in 1930, but later Van Nes 
popularized it. Here the lower limb is rotated by 180
0 
by knee arthrodesis after resection of 
the tumour, such that at skeletal maturity the ankle joint of the short limb should be at the 
level of the contralateral limb knee joint. The foot acts like the residual tibia in a below knee 
amputation. The functional outcome of Van Nesrotationoplasty is significanty better and also 
needs less energy expenditure compared to the use of an above knee prosthesis. 
Some disadvantages with this procedure are the failure to achieve sufficient rotation 
during the procedure, subsequent derotation due to continued growth of the skeleton and the 
unattractive appearance of the leg in which a reversed foot is used. However there are several 
reports of good patient acceptance and functional outcomes and also acceptable cosmetic 
acceptance by the patients, prosthetists and surgeons.
13,14,15,16
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3. Allograft reconstruction. 
In the 1970s the allograft reconstruction was introduced as a biological solution to the 
problem of restoring a segmental defect of the skeleton. There have been significant advances 
in the techniques of fixation of these prostheses and also in the methods of processing the 
graft so as to preserve the articular cartilage and to lessen the contamination. In spite of these 
advances the use of allografts is not very popular due to the high rates of complication and 
prosthesis failure and also due to the stringent means needed to store these grafts.  These 
grafts are procured according to the established guidelines and stored in a fresh frozen state at 
-80
0
C. Even though the allografts are immunogenic the immune response is reduced by the 
non-vascularity of the graft and also due to the freezing which reduces the antigenicity.  The 
osteoarticular allografts have certain advantages compared to the metallic endoprosthesis. 
They provide articular surface for the adjacent bone and obviate the need for resection of the 
articular surface and the growth plate. They also provide ligaments for joint reconstruction 
and including cruciate ligaments and sites for host tendon reconstruction and provides better 
functional outcome than the metallic endoprosthesis. However these advantages are offset by 
significant complications.Early complications are infection,non-union and joint instability, 
and late complications are instability and allograft fracture.The overall complication rate is 
more than 50%,which includes an infection rate of 30%. As a reason this is being done at few 
centres nowadays. This a good option in young patients who are expected to grow and 
develop substantial limb length discrepancies.  
13 
 
 
Fig 2. Allograft reconstruction of a proximal tibial tumour.
18 
 
4. Metallic endoprosthetic reconstruction. 
 Reconstruction of the proximal tibial tumours by endoprosthesis has been a highly 
successful procedure. They are either custom made prosthesis or else modular prosthesis. 
They are made of different alloys, but currently titanium alloy is the preferred one. The 
custom made prosthesis is relatively less expensive than the modular ones. The modular ones 
have the advantage of deciding on table for reconstruction depending upon the amount of 
bone resected. Whereas the custom made prosthesis are prefabricated and is subject to the 
variations in the tumour size and extent changes during therapy. Bone cement that is 
polymethlymethacrylate is usually used to fix this prosthesis. A press-fit porous stem can also 
be used instead of using bone cement. In a retrospective study of 1001 custom made 
prosthesis (which included 493 distal 
14 
 
femoral, 263 proximal femoral and 245 proximal tibial prostheses) aseptic loosening was 
shown to be the principal mode of failure of the implants.
19
 Use of cemented stem allows 
instant fixation which will allow early rehabilitation and mobilization.  
 Improvements in the prosthesis design have also led to the improvements in prosthesis 
survival. In a study by Myers comparing the fixed hinge prosthesis and the rotating hinge 
prosthesis they found risk of revision for any reason in
 
the fixed-hinge group was 32% at five 
years, 61% at ten years
 
and 75% at 15 and 20 years, and in the rotating-hinge group
 
12% at 
five years, 25% at 10 years and 30% at 15 years. The cemented, rotating hinge 
design
 
currently offers the best chance of long-term survival of the
 
prosthesis.
20 
 
Expandable prosthesis is a novel innovation which is very helpful in for replacement 
in skeletally immature patients. In most of the commonly used expanding prosthesis a 
surgical procedure is usually required for the subsequent expansions. A novel type of 
expanding prosthesis called the Stanmore expandable prosthesis (Stanmore Implants, 
Stanmore Middlesex, United Kingdom) uses a noninvasive technique for the prosthesis 
expansion. When the patient with the expandable prosthesis is placed at the centre of a 
rotating electromagnetic field the poles of the magnet within expandable segment of the 
prosthesis are captured, causing it to rotate. The external field rotates slowly at a fixed speed 
causing the implant to expand at a rate of 0.23mm per minute (1mm every 4min).  
 
5. Allograft prosthetic composite. 
 This prosthesis is a transitional step in between the allografts and the metallic 
endoprosthesis. This was introduced when they found out that the complication rates of the 
allografts are significantly high. They provide the advantages of biological reconstruction 
leading to better functional outcomes and also provide the advantage of immediate stability 
15 
 
of the endoprosthesis. However results have shown that this prosthesis also carries the high 
complication rates associated with the allografts. 
21 
 
TECHNIQUES FOR REPAIR OF THE EXTENSOR MECHANISM 
Various techniques have been described in the literature for reconstruction of the extensor 
mechanism at the knee joint. The degree of surgical resection and also the type of prosthesis 
used for reconstruction influence the choice of extensor mechanism reconstruction. No 
randomised trials exist to compare the various methods of extensor mechanism 
reconstruction. The reconstruction options available according to the prosthesis used are 
described briefly below.  
A. Classic endoprosthesis 
Endoprosthesis are a popular means of reconstruction. The main problem with the use of the 
endoprosthesis is the need to attach the patellar tendon to the metal prosthesis. Various 
techniques have been described to overcome this problem.
22 
(a) Direct Fixation: Horowitz et al
23 
presented a series of 16 patients and in 10 patients the 
reconstruction of the extensor mechanism was done by coronally splitting the patella and 
quadriceps tendon and the remnant patella was directly attached to a porous area on the 
anterior surface of the prosthesis. Functional assessment of 6 of these patients revealed an 
extensor lag of less than 20 
0 
in 4 of these patients. However the direct fixation is associated 
with a high rate of complications and the 8 year follow up of this series revealed that 60% of 
these patients had revision or amputation as a result of the complications.  
16 
 
(b) Synthetic soft tissue augments: Many studies have reported the use of textile implants 
such as Dacron tapes, Trevira tube to fix the patellar ligament 
remnant to the prosthesis. 
24, 25
 
The Trevira tube was introduced for extensor mechanism 
reconstruction by Goshegeret al.
26
 „Ligament 
Advancement Reinforcement System (LARS®)‟ which is 
essentially a polyester ligament used to repair the defect in the 
patellar ligament and is secured to the prosthesis at the level of tibial 
tuberosity and also distally at the level of the prosthesis and tibial 
end interface.
27
 Excellent or good functional results were achieved 
in 59% of the patients but ligament failure was seen in 23% (5 
patients).  
 
 
Fig 3. Modular endoprosthetic system Munich-Luebeck, EskaOrthodynamics GmbH,  
uebeck, Germany with the tibial fixation device for the double-layered Trevira cord
24 
 
(c) ‘Biological’ augmentation with or withoutsynthetic materials 
Bickels tried to overcome the lack of healing of the attachment of the extensor apparatus by 
doing a biological fixation.
25 
He used a Dacron® tape to secure the patellar tendon to the 
prosthesis.  He used autologous bone graft to pack the patellar tendon and prosthesis interface 
and covered it with medial gastrocnemius muscle flap. This provided certain advantages: 
immediate mechanical fixation, biological reinforcement to the extensor mechanism, and 
vascularised tissue coverage to minimise infection and facilitate healing. 
17 
 
The biological reinforcement done undergoes osseointegration to the underlying porous-
coated surface of the endoprosthesis. At 12 weeks a layered tendon – fibrocartilage – bone 
interface can be seen which resembles a normal tendon insertion. Quality of repair was also 
robust with few patients requiring secondary procedures for reinforcement.  
Kotz and Coombs
22
 reported the use of pedicled fibular graft for attachment of the patellar 
tendon and reconstruction with an endoprosthesis. This provides an advantage of doing a 
biological reconstruction without the use of synthetic material. The fibular graft was based on 
the peroneal vessels and attached to the tibial mid-shaft using screws and its proximal end 
was attached to the patellar tendon.  
 
B. Allograft–endoprosthesis composites 
Though theoretically the composite prosthesis are an attractive option, the high rates of 
failure of the allograft and subsequent failure of the extensor mechanism is discouraging. 
This method of reconstruction is also plagued by a high rate of infection. Donato reported an 
infection rate of 25%.
22
 
 
C. Biologic reconstruction 
Allograft allows direct attachment of the tendons and the ligaments to provide good 
functional outcome. Host patellar tendon is directly attached to the allograft. This can be 
reinforced with muscle flap to minimise the chances of infection and helps in healing. 
Excellent functional outcomes have been reported. In a case series of 34 cases of proximal 
tibial reconstruction using allograft by Ayerzaet al.
22
 they found that the reconstructed tendon 
was stable in all patients at a mean follow up of 52 months. 24 patients had no extensor lag 
and the remaining 10 had a mean lag of 6.5 
0 
. However this technique has a very high 
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complication rate. Clohisy et al reported that 15 of the 16 allografts for the proximal tibia had 
complications and 7 required removal.
22 
 
Muscle Flaps 
The muscle flaps provide the soft tissue coverage for the prosthesis. This reduces the risk of 
infection, facilitates healing and also provides a mechanism for reconstruction of the extensor 
mechanism. Muscle flaps, in particular the pedicled gastrocnemius flap has been very 
popular. This was first used by Dubousset et al. This can be usedas  a muscle or a 
myocutaneous unit. He described two techniques. The first one in which the patellar tendon 
was intact the medial gastrocnemius was transposed anteriorly and sutured to the tendon. 
Here the muscle is not divided at either the proximal or the distal end. In a situation where the 
patellar tendon is deficient the medial gastrocnemius was divided at its distal end and swung 
anteriorly and fixed to the underlying fibula and attached to the patellar tendon.
22
Malawer 
described a technique in which the medial gastrocnemius was rotated over the defect and 
sutured to the borders of the anterior muscles providing a soft tissue cover over the 
prosthesis.
28 
Other flaps described are a combination of gastrocnemius flap and the 
semitendinosus tendon autograft, sartorius, biceps femoris, semitendinosus and 
latissimusdorsi muscle flap.  
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MATERIALS AND METHODS 
Forty one proximal tibialosteosarcoma patients underwent limbsalvage in cancer institute 
between 2001 and 2011.The case records of these patients were reviewed and followed up for 
Quality of life assessment  after limb salvage surgery. 
 
EVALUATION 
Patients suspected of having bone sarcoma were evaluated with X-ray and MRI of the local 
affected part. Metastatic work up was done with Chest X-Ray, CT Chest and Tc99 bone 
scintigraphy. The outside slides and paraffin blocks were procured for patients who had 
undergone biopsy outside. Jamshidi needle biopsy was done at the institute for patients who 
didn‟t have a biopsy done outside.  
 
Tumours are staged according to the 7
th
 edition of the AJCC cancer staging manual
29 
Primary tumour (T) 
TX – Primary tumour cannot be assessed 
T0 – No evidence of primary tumour 
T1- Tumour 8 cm or less in greatest dimension 
T2- Tumour more than 8 cm in the greatest dimension 
T3- Discontinuous tumours in the primary bone site 
 
20 
 
Regional lymph nodes (N) 
NX – Regional lymph nodes cannot be assessed 
N0 – No regional lymph nodal metastasis 
N1 – Regional lymph nodal metastasis 
 
Distant metastasis (M) 
M0 – No distant metastasis 
M1a – Lung metastasis 
M1b – Metastasis to other distant sites 
 
Histological grade (G) 
GX – Grade cannot be assessed 
G1 – Well differentiated – low grade 
G2 – Moderately differentiated – low grade 
G3 – Poorly differentiated 
G4 – Undifferentiated 
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STAGE GROUPING 
STAGE T N M G 
IA T1 N0 M0 G1, G2, GX 
IB T2 N0 M0 G1, G2, GX 
T3 N0 M0 G1, G2, GX 
IIA T1 N0 M0 G3, G4 
IIB T2 N0 M0 G3, G4 
III T3 N0 M0 G3, G4 
IVA Any T N0 M1a Any G 
IVB Any T N1 Any M Any G 
Any T Any N M1b Any G 
 
NEO-ADJUVANT CHEMOTHERAPY 
Neoadjuvant chemotherapy with ifosphamide, adriamycin and cisplatin were given for two 
cycles and the response to chemotherapy was assessed clinically and if necessary radiological 
with MRI. If the patient was found to be a candidate for limb salvage then a scanogram of the 
affected limb was taken and depending on the dimension of the tumour, the bone scan length 
of the lesion and the dimensions of the remaining bone the custom made prosthesis design 
was prepared and ordered for fabrication.  
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Fig 4. Custom made megaprosthesis made of titanium alloy with the grooves for insertion of 
the prolene mesh 
SURGERY 
Surgery is usually performed after 3 to 4 cycles of neo-adjuvant chemotherapy, depending on 
the response to the neo-adjuvant therapy. Repeat imaging is done for reassessment of the 
borderline resectable tumours. Limb salvage surgery is done with custom made mega-
prosthesis.                                                                                                        
23 
 
Surgicalprinciples:                                                                                                                                                         
Adhering to the surgical principles of limb salvage and maintaining thorough aseptic 
precautions at each phase of the surgery isthe key for the successful outcomes and avoiding 
preventable complications. It includes thorough pre-surgical scrub with antiseptic solution the 
day before and on the day of surgery and after induction of anaesthesia.                                                                                                                                           
Incision:                                                                                                                                                                              
Incision is placed on the medial aspect starting at the lower end of the femur and extended 
across the knee joint to the middle or lower third of the leg. Incision should include the 
previous biopsy scar. Thick fasciocutaneous flaps are raised                                                                
Popliteal vessel dissection :                                                                                                                                                                                                  
Early popliteal  exploration is the key to assess the resectabilty of the tumor.                                                                                                                                                                                                                                                                                                    
Popliteal space and trifurcation of the popliteal artery is exposed by dissection. Care should 
be taken to preserve the vascular supplyto the medial gastrocnemius which is by the medial 
sural artery which goes in a posteromedial direction to the geniculate artery. Further vascular 
dissection is done by and dividing the medial gastrocnemius insertion and splitting the soleus 
muscle.                                                                                                                                   
Knee joint exposure:                                                                                                                                                                          
The capsule is incised circumferentially 1 cm away from the tibia and the patellar tendon. 
The cruciate ligaments are visually exposed and transected and the knee joint is opened.  
 
Peroneal nerve exposure and tibiofibular joint resection:                                                                                         
Lateral fasciocutaneous flap is raised to expose the proximal fibula and the peroneal 
nerve.The tibio-fibular joint is resected en-bloc along with the tumour.                                                                                                                                                                                                                                                                                   
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Bone cuts:                                                                                                                                                                                                
Distally tibia is transected 3 to 4 cm from the bone scan uptake margin and proximally 
articular plate of femur is transected and the specimen is removed enbloc.                                                                                                       
Fixation of prosthesis:                                                                                                                                                  
Cut ends of the bone are reamed with reamer to accommodate the prosthesis. Bone cement 
(PMMC) is used to fix up the tibial prosthesis in position after checking the alignment.    
 
Fig 5. Fixing the prosthesis with bone cement after ensuring correct alignment 
Soft tissue and Extensor reconstruction:                                                                                                                    
Extensor mechanism is reconstructed using prolene mesh anchored to the prosthesis and the 
patellar ligament using non absorbable suture material prolene. Medial gastrocnemius is 
mobilized to provide coverage for the prosthesis and mesh and sutured to the muscles in the 
anterior compartment.                                                                                                                                                
25 
 
 
Fig 6. Fixing the prolene mesh to the prosthesis  
 
Fig 7. Fixing the prolene mesh to the distal end of the patellar tendon 
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Fig 8. Medial gastrocnemius muscle flap used to wrap around the prosthesis and the 
reconstructed extensor mechanism 
Wound closure:                                                                                                                                                                            
After ensuring complete haemostasis, suction drains are placed and majority of the wounds 
are closed primarily and some cases required skin grafting  to achieve closure of the wound.          
Rehabilitation 
Patient‟s knee was kept extended to allow the reconstructed extensor mechanism to heal. 
Static quadriceps exercises are begun on day 7, non-weight bearing mobilization is begun at 2 
to 3 weeks, weight bearing mobilization is begun at 4-6 weeks and full weight bearing is 
begun at 6-8 weeks. All the rehabilitation is done under the supervision by our 
physiotherapists.                                                                                                      
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FOLLOW UP 
Patients after completion of treatment were followed up according to the institute protocol. 
Monthly in first year, two monthly in the second year, three monthly in the third year, six 
monthly in the fourth and fifth year and then annually. Every visit includes clinical 
examination, chest x-ray, physiotherapy. Quality of life assessment and extensor lag were 
measured after 6 months of the procedure. Further investigation were done as clinical 
symptoms and sign warranted. 
Extensor lag measurement: 
To measure the extensor lag the patient was put in a high sitting posture and using a 
goniometer the range of movements and the lag in extension from full extension was 
measured.  
 
Fig 9.Measurement of the extensor lag using a goniometer.  
 
COMPLICATIONS AND ITS MANAGEMENT 
Patients after limbsalvage surgery face with varieties of complication and they were managed 
appropriately. Marginal skin necrosis was managed mostly by conservative treatment rarely 
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some required debridement and secondary suturing, skin grafting or local flaps. Major 
complications were approached with redoprosthesis for prosthesis fracture, prosthesis 
removal or amputation for prosthesis infection, amputation for local recurrence and 
metastectomy for resectable lung metastasis in a patient with good performance status and 
adequate disease free survival.  
 
ASSESSMENT OF THE QUALITY OF LIFE AND FUNCTION OUTCOME 
Functional outcome assessment was done using the musculoskeletal tumour society scoring 
system (MSTS)
30
  and Quality of life by Cancer Institute Quality of life Questionnaire 
Version II
31
.                                                                     
 Scoring system – International society of limb salvage 
SCORE PAIN FUNCTION EMOTIONAL 
ACCEPTANCE 
SUPPORTS WALKING 
ABILITY 
GAIT 
5 None No Restriction Enthuse None Unlimited Normal 
4 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate 
3 Moderate Restriction in 
recreational 
activities 
Satisfied Brace Limited Minor 
cosmetic 
2 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate 
1 Moderate Partial disability Accepts One cane or 
crutch 
Household Major 
cosmetic, 
minor 
handicap 
0 Severe Total disability Dislikes Two canes or 
crutches 
Unable to 
walk unaided 
Major 
cosmetic, 
minor 
handicap 
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Cancer Institute QOL questionnaire
31
 consisted of 42 variables and the maximum score was 
180. Higher the score better the quality of life.  The interpretation of the QOL II version is as 
follows:  
1. <99 – Significantly poor 
2. 99-117 – Below average 
3. 118-146 – Average 
4. 147 – 165 – Above average. 
5. >165 – significantly high 
STATISTICAL ANALYSIS 
Statistical analysis was done by SPSS 17 (SPSS software Inc USA). Extensor lag and quality 
of life assessment were analysed by T –test. 
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RESULTS 
41 consecutive patients who underwent limb salvage surgery for proximal tibial 
osteosarcomas from 2001 to 2011 were analysed.  
Mean age of the patients was 17.7 years (range 9-35 years). There were 15 patients with age 
more than 18 years and 26 patients with age up to 18 years.  
29 patients (70.7%) of the patients were male and 12 patients (29.3%) were females.  
J needle biopsy was used for the diagnosis in 32 patients (78%) and open biopsy was 
performed in 9 patients (22%). Of note, no open biopsies were performed in our institute. All 
of the 9 open biopsies were done outside and the slides were reviewed here.  
Preoperative biopsy was the follows 
Histiology Frequency 
Classical osteosarcoma high grade 19 
Chondroblastic osteosarcoma 8 
Pleomorphic sarcoma 11 
Fibroblastic osterosarcoma 1 
Giant cell tumour of bone 1 
Chondrosarcoma 1 
 
The average bone scan length was 13.5 cms and 30 patients had bone scan length of up to 15 
cms and 11 patients had bone scan length more than 15 cms.  
CT chest done upfront showed nodules in the chest in 4 patients. Among these patients 3 had 
solitary pleural based nodule and 1 patient has 2 nodules. However only one patient among 
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the three with solitary nodule in the chest developed lung metastases after limb salvage with a 
DFS of 20.2 months and he underwent metastectomy twice. His overall survival was 70.1 
months.  
Neoadjuvant chemotherapy was given in all but 2 patients. These two patients had a 
preoperative diagnosis of giant cell tumour of the bone and chondrosarcoma respectively. 32 
patients received either 3 or 4 cycles of neoadjuvant chemotherapy. 7 patients received either 
5 or 6 cycles of neoadjuvant chemotherapy.  
16 patients underwent reconstruction with endoprosthesis and myoplasty (gastrocnemius 
muscle flap) and 25 patients underwent reconstruction with mesh-myoplasty (using prolene 
mesh for reconstruction of the extensor mechanism). 31 patients had resection of the fibular 
head and 22 patients had ligation of the anterior tibial artery during resection of the tumour. 6 
patients needed SSG cover during the procedure.  
 
Early complication  
Complications occurring within 30 days of the surgery were considered as early 
complications.  
Early complication Frequency Treatment  
Foot drop 14 Conservative  
Skin necrosis 6 Conservative (2), flap cover (1) and 
secondary suturing (3) 
Foot drop and skin 
necrosis 
1 Conservative  
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Over all 51.2% patients had early minor complications. However about 50% of them were 
foot drops which recovered in most of the patients. None of them had any major complication 
in the early postoperative period for which removal of prosthesis was necessary. 
Complications occurring after 30 postoperative days were considered as late 
complications. Over all 10 patients had late complications (24.4%). 
Late complication Frequency Treatment  
Infection 3 Prosthesis removal (2)  
Amputation (1) 
Fracture prosthesis 2 Redoprosthesis (1)  
Patient was not willing for 
redoprosthesis (1)   
Aseptic loosening 3 Redoprosthesis (3) 
Exposed prosthesis 1 Prosthesis removal 
Fracture of the limb proximal to the 
prosthesis 
1 Open reduction and internal fixation  
 
Post-operative histopathology 
Histology Frequency  
Classical osteosarcoma 23 
Chondroblastic osteosarcoma 9 
Pleomorphic sarcoma  1 
No residual tumour 7 
Giant cell tumour rich osteosarcoma 1 
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Tumour necrosis: 
Percentage of necrosis in the post-operative specimen was examined 
Percentage of necrosis Frequency 
>90
0 
9 (22%) 
0
0
 to 90
0 
32 (78%) 
 
Recurrence: 
10 patients (24.4%) had recurrence on followup.  
Site of recurrence Frequency 
Local 1 
Distant 8 
Local and distant 1 
 
Overall only 2 patients (4.8%) had local recurrence and 9 patients (21.95%) had lung 
metastasis. The patient with both local and distant recurrence was offered only supportive 
care. The patient with only local recurrence defaulted for evaluation. Of the 8 patients with 
only distant metastasis 6 were offered supportive care (due to multiple bilateral 
metastasis)and 1 patient underwent metastectomy twice and had chemotherapy. The other 
patientunderwent metastectomyonce.  
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Survival analysis was done using SPSS 17.0 version and Kaplan Meyers analysis. 
5 years overall survival and disease free survival were 85.5% and 70.6% respectively. In both 
the overall survival and the disease free survival the events occurred during the first 2 years.  
The mean overall survival was 38 months and mean disease free survival was 34 months.  
 
 
 
 
 
 
 
Factors like age of the patient, type of biopsy, bone scan length of the lesion, number of 
preoperative chemotherapy cycles, type of surgery and amount of necrosis in the post-
operative specimen were evaluated for impact on survival.  
Among these there was a statistically significant difference in survival only in patients 
receiving 3 to 4 cycles of neo-adjuvant chemotherapy versus those receiving 5 to 6 cycles of 
neo-adjuvant chemotherapy with the 5 year overall survival being 94.1% versus 68.6% 
respectively  
(p= 0.045) 
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S.No Variable 5 year overall survival 
in % 
p value 
1.  Age upto 18 years 81.4 NS 
 Age > 18 years 93.3  
2.  Bone scan length upto 15 cms 85.7 NS 
 Bone scan length >15 cms 90.9  
3.  J needle biopsy 84.3 NS 
 Open biopsy 87.5  
4 3 to 4 cycles pre op chemo  94.1 0.045 
 5 to 6 cycles pre op chemo 68.6  
5 Myoplasty 86.7 0.885 
 Meshmyoplasty 84.7  
6 Necrosis upto 90% 84.6 NS 
 Necrosis >90% 87.5  
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Disease free survival: 
Similarly these factors were analysed for any influence on the disease free survival. 
S.No Variable 5 year Disease free 
survival in% 
p value 
1.  Age upto 18 years 64.8 NS 
 Age > 18 years 80  
2.  Bone scan length upto 15 cms 64.3 NS 
 Bone scan length >15 cms 90.9  
3.  J needle biopsy 75.5 NS 
 Open biopsy 53.3  
4 3 to 4 cycles pre op chemo  76.9 NS 
 5 to 6 cycles pre op chemo 53.6  
5 Myoplasty 80.8 NS 
 Meshmyoplasty 62  
6 Necrosis upto 90% 68.5 NS 
 Necrosis >90% 77.8  
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Prosthesis survival: 
 The mean prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). The 5 
year prosthesis survival was 86.5%. All of the prosthesis failures occurred in the first 3 years. 
Prosthesis survival was analysed with respect to bone scan length, type of surgery (myoplasty 
versus meshmyoplasty), depending on the type of the biopsy and whether the patient received 
3 to 4 or 5 to 6 cycles of pre-operative chemo.  
 
S.No Variable 5 year prosthesis 
survival in% 
p value 
1.  Bone scan length upto 15 cms 89.8 NS 
 Bone scan length >15 cms 85.7  
2.  J needle biopsy 88.7 NS 
 Open biopsy 77.8  
3.  3 to 4 cycles pre op chemo  89.3 NS 
 5 to 6 cycles pre op chemo 71.4  
4 Myoplasty 93.8 NS 
 Meshmyoplasty 79.9  
 
There was no statistically significant difference in the prosthesis survival between the cases 
that underwent myoplasty and meshmyoplasty. 
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Quality of life assessment: 
Quality of life assessment was done based on the Cancer Institute QOL questionnaire II for 
cancer patients
31
and the MSTS scoring system
30
 was used for the functional outcome.  
Of the 41 patients 4 of the patients were lost to follow-up and were not available for QOL 
assessment. 2 patients died and 2 patients had their prosthesis removed before the time of 
QOL assessment. So QOL was done for 33 patients and among these 24 had undergone 
meshmyoplasty and 9 had undergone myoplasty. Following are the results of the analysis.  
 
QOL Variable Myoplasty Mesh-myoplasty p Value using T test 
QOL total 148.89 144.17 0.197 
General  well being 25.78 23.71 0.075 
Physical well being 37.11 36.0 0.139 
Psychological well 
being 
23.89 24.71 0.627 
Interpersonal 
relationship 
15.44 14.63 0.207 
Sexual and personal 
ability 
4.78 4.50 0.713 
Cognitive well being 11.00 11.21 0.642 
Optimism and belief 7.67 7.50 0.599 
Economical well 
being 
8.78 8.67 0.875 
Information support 7.56 6.46 0.035 
Patient physician 
relationship 
4.00 3.88 0.414 
Body image 2.89 2.92 0.937 
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QOL analysis between the two type of surgeries i.e. myoplasty and mesh-myoplasty did not 
show any statistically significant outcomes in the overall quality of life. However  theover all 
QOL was slightly better in the analysis done for information support. Information support 
was concerned with the amount of information the patient expected and the amount of 
information the patients were able to get from the doctors.  
 
Functional outcome was assessed using the MSTS scoring system
30 
A total of 6 factors were analysed and the following are the results. 
MSTS variable Myoplasty (mean) Mesh-myoplasty 
(mean) 
p Value using T test 
PAIN 4.78 4.67 0.599 
FUNCTION 3.56 3.33 0.479 
EMOTIONAL 
ACCEPTANCE 
2.89 3.50 0.031 
SUPPORTS 4.44 4.54 0.748 
WALKING ABILITY 3.56 3.29 0.397 
GAIT 3.11 3.04 0.805 
TOTAL 22.33 22.38 0.964 
 
 
This shows that the overall functional outcome between the patients undergoing myoplasty 
and mesh-myoplasty was similar. However when the patients were analysed based on the 
emotional acceptance of the patients, the patients undergoing mesh-myoplasty showed a 
statistically better outcome (p=0.031) than the group undergoing myoplasty. 
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EXTENSOR LAG ANALYSIS 
Extensor lag was measured for 32 patients (8 with myoplasty and 24 with 
meshmyoplasty). 4 patients were lost to follow up, 3 patients were dead and 2 patients had 
their prosthesis removed due to infection prior to the time when the extensor lag was 
measured.  
The mean extensor lag in the patients undergoing myoplasty was 68.13
0 
and the mean 
extensor lag in the patients undergoing mesh-myoplasty was 36.66
0 
and the difference was 
statistically significant (p=0.004).  
 
Type of surgery 0
0 
1
0
 – 200 210 – 500 510 – 700 >700 
Myoplasty 0 0 1 3 4 
Mesh-myoplasty 2 5 13 1 3 
 
None of the patients in the myoplasty arm had an extensor lag of less than 21
0 
. Whereas 2 
patients with mesh-myoplasty had 0
0 
extensor lag. 
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DISCUSSION 
 The management and the outcomes including the survival and the functional 
outcomes of proximal tibial osteosarcomas has changed considerably due to the use of 
chemotherapy, use of advanced imaging technology and refinements of surgical techniques. 
The prosthesis survival also has increased due to use of better quality and designing of 
prosthesis. Endoprosthetic reconstruction is now the preferred method used for reconstruction 
with various methods used for reconstruction of the extensor mechanism which is one of the 
important factors affecting the functional outcomes.  
 In our study we included 41 consecutive cases of proximal tibial osteosarcomas who 
underwent limb salvage surgery at our institute from 2001 to 2011 with a mean follow up of 
38 months. 
 The mean age of the patients was 17.7 years (range 9-35 years). There were 15 
patients with age more than 18 years and 26 patients with age up to 18 years. In the German-
Austrian-Swiss co-operative study group comparison of the overall survival of the patients 
with age of the patients <40 years and >=40 years showed statistically significant difference 
in favour of the group less than 40 yrs of age 
Our study did not show any statistically significant difference in the age group =< 18 years 
and > 18 years. 
Generally many studies have shown that proximal tibial osteosarcomas are a 
favourable sub-site for the sarcomas
19, 32
.  
 The Cooperative German-Austrian-Swiss Osteosarcoma Study Group
32 
in their 
analysis of 1702 cases of osteosarcomas found that the tumours in the proximal tibia had a 
5year and 10 year overall survival of 77.5% and 72.0% respectively, whereas the overall 
survival in the entire group for 5 years and 10 years was 65.3% and 59.8%. 
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 In the Brazilian osteosarcoma treatment group studies III and IV by SérgioPetrilliet 
al
34
, they found that the overall 5 and 10 year survival was 50.1% and 46.7% whereas it was 
60.0% and 56.7% respectively for tumours arising in the proximal tibia 
However in our study we have included only cases which had small volume tumours 
with better prognosis and who have undergone limb salvage surgery where as the other 
studies quoted have included cases with metastasis and also patients who have undergone 
amputation.  
 Various studies have shown that the outcomes with larger tumour volumes have been 
poorer
32, 33
. In our study we used the bone scan length of the tumour to classify them into 2 
categories. They were classified as tumour with bone scan length =<15 cms (30 patients – 
73.2%) and tumours >15 cms (11 patients – 26.8%). We did not find any statistically 
significant difference in the survival in these two subgroups.  
 If patients are having extensive soft tissue component then it is one of the relative 
contraindications to performing limb salvage surgery. Spanier et al. from the University of 
Florida have extensively studied the effect of local extent of the tumour on disease free 
survival and overall survival.
35 
 They studied the effect of the local tumour extent on the disease free survival. They 
included 51 patients with Enneking stage IIB tumours. They classified the tumours into 6 
types depending on the local extent of the tumour.  
E1 – Tumour only touches the periosteum but does not elevate or penetrate it.  
E2 – Tumour touches and elevates the periosteum but does not penetrate it.  
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E3 – Tumour penetrates into the periosteum but does not penetrate through the periosteum. 
E4 – Tumour penetrates through the periosteum with minimum extraperiosteal extension 
without invasion of another structure (like muscle, tendon or ligament) 
E5- Tumour invades one additional structure  
E6 – Tumour invades two or more additional structures.35 
They found that the risk of failure was 5.9 times higher if tumour involed 2 or more 
surrounding tissues compared to the other subgroups.
35
 
  
Study Size of the 
tumour 
OS p Value DFS p Value 
German-Austrian-Swiss group
32 
< one third 72.1% <.0001 61.0% <.0001 
>= one third  58.4% 42.9% 
Bacci et al
33 
based on the tumour 
volume 
=<150 ml    65% NS 
>150 ml  52% 
SérgioPetrilli et al
34  
-tumour 
length 
=<12cms 64.5% <.0001 48.1% .009 
>12 cms 40.5% 30.4% 
Spanier SS, Shuster JJ, Vander 
Griend RA
35 
E1 – E5 82.3%  79.8%  
E6 37.8% 17.6% 
Our study – Bone scan length =<15cms 85.5% NS 64.8% NS 
>15 cms 64.3% 90.9% 
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Chemotherapy  
The use of chemotherapy has brought about a revolution in the outlook of these 
previously lethal tumours. The advantages of giving preoperative chemotherapy include: 
1. Early initiation of the systemic therapy. 
2. Borderline cases for limb salvage can undergo limb salvage surgery following tumour 
shrinkage after chemotherapy. 
3. The response of the tumour to the chemotherapy can be assessed.  
4. Provides time for designing and fabrication of the custom made prosthesis. 
However the disadvantage is that the chemotherapeutic agent has to act against a large 
tumour burden.   
Pediatric oncology group conducted a randomised control trial POG 8651, to compare the 
preoperative chemotherapy versus adjuvant chemotherapy. Of the 100 patients 45 underwent 
preoperative chemotherapy and 55 underwent straight surgery followed by chemotherapy. 
The 5 years DFS for undergoing immediate surgery and preoperative chemotherapy was 65% 
and 61 % (p -.8) and the rate of limb salvage for these groups were 55% and 50% 
respectively. It was concluded that chemotherapy was effective in both the settings
36
. In our 
study 2 patients did not receive a preoperative chemotherapy because the preoperative 
diagnosis for these patients was giant cell tumour of the bone in one case and 
chondrosarcoma in the other case. As the number of cases undergoing immediate surgery was 
very less statistical analysis couldn‟t be done.  
The response to neo-adjuvant chemotherapy has been an important prognostic factor 
for the overall and the disease free survivals. Several centres have developed criteria to 
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evaluate the chemotherapy response. Huvos et al. at MSKCC
37
, Salzer-Kuntschik et al.
38
 ( 
system used by the COSS study group) and Picci et al 
39 
at InstitutiOrthopedico Rizzoli 
independently developed criteria to assess the tumour response to chemotherapy. But as a 
consensus a tumour response >90% is taken as good response and =<90% is taken as poor 
response.  
Using this criterion the chemotherapy response was assessed in our study and 30 
patients (76.92%) were poor responders and 9 (22%) were good responders. 
Response to chemotherapy has been reported by various studies and has been a 
statistically significant predictor of survival
32, 34, 40
. However the update by Bacciet al
33 
did 
not show any statistically significant difference in the outcomes of poor responders to 
chemotherapy compared to the good responders.  
Huvos et al
37 
Salzer-Kuntschik et al.
38
 Picci et al 
39
 
IV No histologic evidence 
of viable tumor 
I No viable tumor cells Good 
response 
90%-99% 
tumor 
necrosis 
III Only scattered foci of 
viable tumor cells 
II Single viable tumor 
cells or cluster <0.5 cm 
Fair response 60%-89% 
tumor 
necrosis 
II Areas of necrosis due to 
chemotherapy with 
areas of viable tumor 
III Viable tumor<10% Poor 
response 
<60% tumor 
necrosis 
I Little or no 
chemotherapy effect 
IV Viable tumor 10% - 
50% 
  
  V Viable tumor>50%   
  VI No effect of 
chemotherapy 
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Response to preoperative chemotherapy and survival outcomes 
Study  Disease free survival p value Overall survival p value 
Good 
responders 
Poor 
responders 
 Good 
responders 
Poor 
responders 
 
COSS study
32 
67.6% 38.6% <.0001 77.8% 73.4% <.0001 
SigbjornSmeland 
et al
40 
89% 53% .004    
Bacci G
33 
62% 51% NS    
Our study 68.5% 77.8% 0.539 87.5% 84.6% 0.521 
 
Even though our study did not reveal a significant difference in the survival of the patients 
with poor response to preoperative chemotherapy compared to the patients with good 
response, the survival curves never met and may be with more number of patients or a longer 
follow up we may be able to appreciate a difference in survival between these subgroups.  
 We also analysed the survival of the patients who had received 3 to 4 cycles of 
preoperative chemotherapy versus those receiving 5 to 6 cycles of preoperative chemo. We 
found that patients receiving 3 to 4 cycles of chemotherapy had a statistically significant 
better overall survival ( 94.1% versus 68.6% with p = .045 ) compared to the patients who 
received 5 to 6 cycles of chemotherapy. 
 We also analysed the survival outcomes with respect to type of surgery (myoplasty 
v/s meshmyoplasty), whether the fibular head was resected or not, whether the anterior tibial 
artery was ligated or not and also depending on the type of biopsy (J needle biopsy versus 
open biopsy). The survival outcomes between the above compared subgroups were not 
different statistically.  
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Recurrences 
There were 10 cases of recurrence in our series. 1 patient had local recurrence, 1 patient had 
both local recurrence and distant metastasis and 8 patients had lung metastasis. The mean 
duration for recurrence or metastasis was 14.97 months (range 4.9 to 26.3 months). The local 
recurrence rate was 4.8% (2 patients) and the distant recurrence rate was 21.95% (9 patients). 
Most of the published series for limb salvage surgery have documented involved margins, 
larger size of the tumour, open biopsy, local response to chemotherapy and low volume 
centres as significant predictors for local recurrence. 
41, 42, 43, 44, 40, 34 
In our study none of the patients had margin positivity and as the number of local recurrences 
was only 2 statistical analyses couldn‟t be done.  
Our local recurrence rates are comparable with the major published series.  
Study Local recurrence rate 
P. Picci et al
41 
7% 
D. Andreou et al
42 
5.6% 
Sigbjorn Smeland
40 
4% 
A. Sérgio Petrilli
34 
10% 
Torbert, Jesse T MD et al
43 
6.8% 
Bacci G et al
44 
6% 
 
12.6% 
Our study 4.8% 
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Prosthesis survival  
 The mean prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). 
The 5 yr prosthesis survival was 86.5%. All of the prosthesis failures occurred in the first 3 
years. Prosthesis survival was analysed with respect to bone scan length, type of surgery 
(myoplasty versus meshmyoplasty), depending on the type of the biopsy and whether the 
patient received 3 to 4 or 5 to 6 cycles of pre-operative chemo. There was no statistically 
significant difference in the above compare subgroups. 
 Our prosthesis survival of 86.5% is comparable to the various studies quoted in the 
literature regarding the prosthesis survival. 
 
 
Study  Proximal tibial Prosthesis survival 
5 years 10 years 
MayilVahananNatarajan et al.
45 
85.5  
Adam J. Schwartz MD et al.
46 
93.8% 86.5% 
G. J. C. Myers
20 
(fixed hinge) 68% 39% 
G. J. C. Myers
20 
(rotating hinge) 88% 75% 
Flint et al.
47 
(fixed hinge) 73%  
Wu et al
48 
(custom prosthesis) 44.4% 22.2% 
Wu et al
48 
(modular prosthesis) 81.4% 65.3% 
Our study (over all) 86.5%  
Our study (myoplasty) 93.5%  
Our study (meshmyoplasty) 79.9%  
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Even though the 5 yr prosthesis survival was better in the myoplasty arm it did not reach 
statistical significance. The 8 year prosthesis survival was 64.3% for the myoplasty arm and 
79.9% for the meshmyoplasty arm. Most of the events have occurred in the first 3 years. 
However we need a longer follow up with the meshmyoplasty arm to clearly tell us about the 
long term outcomes.  
Complications 
 Early complications were taken as the complications occuring within 30 days of the 
surgery. Of the 41 patients 14 patients had a temporary foot drop which recovery in all but 2 
of the patients on followup. 6 patients has mariginal skin necrosis which was managed 
conservatively in 2, by flap cover in 1 and with secondary suturing in 3 patients. 1 patient had 
both foot drop and marginal skin necrosis and was managed conservatively 
 Late complications were taken as those occuring after 30 days of the surgery. In our 
series 10 patients (24.4%) had late complications.  The following were the complication 
breakdown and the treatment given for them.  
Late complication Frequency Treatment  
Infection 3 (7.31%) Prosthesis removal (2)  
Amputation (1) 
Fracture prosthesis 2 (4.87%) Redoprosthesis (1)  
Conservative treatment(1)   
Aseptic loosening 3 (7.31%) Redoprosthesis (3) 
Exposed prosthesis 1 (2.43%) Prosthesis removal 
Fracture of the limb proximal to the 
prosthesis 
1 (2.43%) Open reduction and internal fixation  
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In most of the series reported on proximal tibial prosthesis, infection and aseptic loosening 
has been stated as most common causes for prostesis failure.  
Here we compare the infection rates, asceptic loosening rates and prosthesis loosening rates 
of our study with the other studies stated in literature. 
 
 
Study Infection  Asceptic 
loosening 
Fracture 
prosthesis 
Our study 7.31% 7.31% 4.87% 
 
With gastrocnemius 12% - 3.31% 
(5/151) Without gastrocnemius 36% 
P. S. Unwin et al.
19
 36.58% 19.51% 4% 
Jacob Bickels et al
25
 3.6% - 3.63% 
Myers et al
20 
Fixed hinge  19.5% 46% 1.92% 
Rotating hinge 3% 
Flint MN et al
47 
Uncemented prosthesis 15.9% 0% 4.54% 
Adam J. Schwartz et a.l
46 
5.8% 11.53%  
MayilVahananNatarajan et al.
45 
12%   
Wu CC et al.
48 
15.9%   
Horowitz et al.
23 
37.5%   
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 The major complications in the proximal tibial prosthesis are infection, aseptic 
loosening and fracture of the prosthesis stem. Infections rates have come down with the use 
of adequate soft tissue cover, basically used is the medial gastrocnemius muscle flap.  
Aseptic loosening of the prosthesis is another complication in which the use of prosthesis 
with a rotating hinge has reduced the incidence. Recent reports of using uncemented 
prosthesis have also reported a reduction in the rates of aseptic loosening.  
 So these technical modifications have reduced the complication rates in this 
anatomical site which traditionally has a higher complication rate.  
 
Quality of life assessment  
 QOL was analysed by the Cancer Institute QOL Questionnaire
31 
which is based on 42 
questions and based on that scores are given. Higher the scores better the QOL. 
The score of the patients undergoing myoplasty was 148.89 which is just above the average 
score, and the score of the patient undergoing mesh-myoplasty was 144.17 which is in the 
higher range of average scores. There was no statistically significant difference in the quality 
of life of the patients undergoing myoplasty or mesh-myoplasty.  
 None of the factors subgrouped to denote different aspects of the quality of life 
showed any difference in the two groups except the aspect of information support.  
 Over all the quality of life was satisfactory. 
Functional outcome assessment. 
 Functional outcome was assessed using MSTS scoring system
30
. The mean MSTS 
score was 22.35 (74.5%). It was 22.33 in the patients undergoing myoplasty and 22.38 in the 
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patients undergoing mesh-myoplasty. Comparison of the functional outcome between the two 
groups was not statistically significant. However while analysing the scores concerned with 
„emotional acceptance‟ there was a statistically significant difference in favour of the group 
in which the reconstruction was done using mesh-myoplasty.  
The MSTS score of our series was comparable with those in the other series. 
 
Study  MSTS score 
 77% 
Vijay Titus MS
49
82.1% 
Adam J. Schwartz MD et al.
46
 82% 
Zhang Y.
50 
(tibiofibular joint involved) 70% 
Flint MN et al
47
 75% 
Our study 74.5% 
 
As compared above the functional outcomes of the patients in our series is satisfactory. 
Extensor lag 
 The active extensor lag for the patients undergoing myoplasty was 68.13
0
and for the 
patients undergoing mesh-myoplasty was 38.81
0
. The difference in the outcomes was 
statistically significant in favour of the group undergoing mesh-myoplasty (p=0.004). No 
revision surgeries were done in our surgeries for the repair of the extensor mechanism.  The 
following table compares the outcomes of the extensor lag of our series with that of other 
series. 
 
53 
 
Study Mean Extensor Lag 
Our study (myoplasty) 68.13
0
 
Our study (mesh-myoplasty) 38.81
0 
 30
0 
Adam J. Schwartz MD et al.
46
17.9
0 
Flint MN et al
47
 6
0 
Vijay Titus MS
49
 4
0  
Dominkus M
27 
25
0 
Gosheger G
26 
7.5
0 
Shimose S
51 
26
0 
 
Though the extensor lag in the mesh-myoplasty arm in our series was significantly better than 
the arm which underwent myoplasty alone, it was more than some of the other studies. The 
extensor lag in our series could be further improved by  
1. Considering revision surgery for the extensor mechanism for patients with poor extension.  
2. Extensor mechanism could be augmented with bone grafts, wire cerclage, etc. 
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CONCLUSION 
1. With the use of effective modern chemotherapy osteosarcoma treatment has seen a 
paradigm shift. Excellent survival results are seen in the proximal tibial osteosarcomas in our 
study which is at par with the international studies. Patients receiving 3 to 4 cycles of 
preoperative chemotherapy showed better survival outcome than those receiving 5 to 6 cycles 
of preoperative chemotherapy, thought it was not statistically significant. Good responders to 
preoperative chemotherapy also showed a trend towards better survival though it was not 
statistically significant. 
2. Limb salvage surgery has been very satisfactorily done for the proximal tibial 
osteosarcomas, which is traditionally considered a difficult site to reconstruct.  
3. Prosthesis survival at this site is influenced by a high rate of complications which include 
infection, prosthesis loosening and fracture of the prosthesis. The modifications of the 
surgical techniques and use of flaps for soft tissue cover has significantly reduced these 
complications.  
4. There was no statistically significant difference in the prosthesis survival times of the 
patients undergoing myoplasty versus those undergoing mesh-myoplasty.  
5. The extensor lag was significantly better in the patients undergoing mesh-myoplasty, but 
compared to international studies it was slightly inferior. We may need to consider the use of 
bone grafts augmentation for better bio-integration of the extensor mechanism.  
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ABSTRACT 
 
Limb salvage surgery in osteosarcomas of the upper end of the tibia encompasses 
several challenges. Among those challenges lack of soft tissue cover, higher rates of 
prosthesis failure and difficulty in reconstructing extensor mechanism of the knee joint are 
important.  
Retrospective analysis of 41 consecutive patients undergoing limb salvage surgery for 
proximal tibialosteosarcomas at our institute from 2001 to 2011.16 patients underwent 
reconstruction with endoprosthesis and myoplasty (gastrocnemius muscle flap) and 25 
patients underwent reconstruction with mesh-myoplasty (using prolene mesh for 
reconstruction of the extensor mechanism). The 5 yr overall survival and disease free survival 
was 85.5% and 70.6%. Patients who has 3 to 4 cycles of preoperative chemotherapy had 
significantly better 5 year overall survival then those who received 5 to 6 cycles of 
chemotherapy. (94.1% versus 68.6%). 9 patients (22%) had tumour necrosis >90% and 32 
patients (78%) had tumour necrosis =<90%, but there was no statistically significant 
difference in the overall survivals of these two groups (87.5% versus 84.6%). The mean 
prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). The 5 year 
prosthesis survival was 86.5%. Infection (3), aseptic loosening (3) and fracture of the 
prosthesis (2) were the main reasons for prosthesis failure. There was no statistically 
significant difference in the prosthesis survival between the cases that underwent myoplasty 
and meshmyoplasty. 
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Quality of life analysis was done using the Cancer Institute QOL questionnaire II and 
functional outcomes were evaluated with MSTS scoring system (mean score 74.5%). There 
was no statistically significant difference in the quality of life outcomes or functional 
outcomes according to these scoring systems. But the mean extensor lag in the patients 
undergoing myoplasty was 68.13
0 
and the mean extensor lag in the patients undergoing mesh-
myoplasty was 36.66
0 
and the difference was statistically significant (p=0.004). 2 patients 
with meshmyoplasty had 0
0 
extensor lag whereas none of the patients with myoplasty had 0
0 
extensor lag.  
8 patients had lung metastasis, 1 patient had local recurrence and 1 patient had both 
local recurrence and lung metastasis.  
The prosthesis survival and the functional outcomes (MSTS scores) in our series is 
comparable to the other series in literature on endoprosthetic reconstruction for proximal 
tibial osteosarcomas.  
Keywords: Custom made endoprosthesis, proximal tibial osteosarcoma, limb salvage surgery 
 
1 
 
 
AIMS OF THE STUDY 
 
1. TO STUDY THE SURVIVAL OUTCOMES OF THE PATIENTS UNDERGOING 
LIMB SALVAGE SURGERY IN PROXIMAL TIBIAL TUMOURS WITH 
CUSTOM MADE MEGAPROSTHESIS. 
 
2. TO COMPARE THE QUALITY OF LIFE ASSESSMENT BETWEEN GROUPS 
UNDERGOING EXTENSOR MECHANISM RECONSTRUCTION WITH OR 
WITHOUT A PROLENE MESH. 
 
3. TO STUDY THE EARLY AND LATE COMPLICATIONS. 
 
 
4. TO STUDY THE PROSTHESIS SURVIVAL TIME AND THE FACTORS 
AFFECTING PROSTHESIS SURVIVAL. 
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  INTRODUCTION 
“Walking is man’s best medicine”     - Hippocrates 
Bony sarcomas arising from the proximal end of the tibia constitute the second most 
common site of occurrenceafter the distal end of the femur.  However this area is a difficult 
site to perform a safe limb sparing resection in which function is preserved due to anatomical 
constraints and also surgical technique. Historically amputation had been the treatment for 
bony sarcomas. The use of effective chemotherapeutic regimen,  modern imaging technology 
and advances in surgical techniques has broadened the horizon and scope of limb salvage 
surgery in this site. The primary difficulty in doing a limb salvage surgery for sarcoma of the 
proximal tibia is due to the local anatomy. A difficult surgical approach, intimate relationship 
to the neurovascular structures, inadequate soft tissue coverage are few of the challenges 
surgeons face during procedures at this site. Another important factor is the need to 
reconstruct the extensor mechanism of the knee joint. Many surgical techniques and 
reconstruction mechanisms have been described for the tumours at this site and have 
provided satisfactory survival and functional outcomes. 
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REVIEW OF LITERATURE 
HISTORY OF BONE SARCOMAS 
Osteosarcoma as a disease was recognised since ancient times. An English surgeon 
named John Abernathy coined the term “sarcoma” in 1804 which was derived from Greek 
roots and means “fleshy excrescence.”1  Alexis Boyer a French surgeon ( personal surgeon to 
Napoleon ) recognised that sarcomas arising in the bone are a distinct entity from other bony 
lesion and is credited with using the term osteosarcomas for the first time in 1805.
1 
The gross pathological appearance of this tumour was accurately described by 
Guillaume Dupuytren in 1847. He the described the appearance as the following: 
"Osteosarcoma, which is a true cancerous degeneration of bone, manifests itself in the 
form of a white or reddish mass, lardaceous and firm at an early stage of the disease; but 
presenting at a later period, points of softening, cerebriform matter, extravasating blood, and 
white or straw coloured fluid of a viscid consistence in its interior.”1 
As there was limited experience to guide the surgeons of that time a Registry of Bone 
Sarcoma was created in 1921 under the auspices of the American College of Surgeons, by 
Ernest Amory Codman (along with James Ewing and Joseph Bloodgood).
2 
Great advances were made in the field of pathology of bone tumours in the mid-
1900s. Henry Jaffe and Louis Lichtenstein published textbooks on bone pathology that 
established many of the important pathological criteria which are used to diagnose the 
commonly seen bone tumours. 
Dr Norman Jaffe and few others popularised the use of chemotherapeutic drugs for 
osteosarcomas in the 1970s and early 1980s.
3 
Most commonly Adriamycin and methotrexate 
were used. At MSKCC Rosen found out that these chemotherapeutic drugs useful both 
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preoperatively as well as postoperatively while studying the patients who were awaiting the 
custom made prosthesis for their surgery.
4 
William F. Enneking is an eminent name in the field of orthopaedic oncology. He 
introduced the a surgical staging system for bone sarcomas and trained many orthopaedic 
oncology fellows, several research papers have been published by him and actively 
conducted continuing medical education course on bone tumours. 
The staging system described by Enneking et al is based on GTM: grade(G), 
location(T), lymph node involvement and metastasis (M). The staging system is as follows: 
 
Stage IA (G1 T1 M0): Low grade intra-compartmental lesion, without metastasis. 
Stage IB (G1 T2 M0): Low grade extra-compartmental lesion, without metastasis. 
Stage IIA (G2 T1 M0): High grade intra-compartmental lesion, without metastasis. 
Stage IIB (G2 T2 M0): High grade extra-compartmental lesion, without metastasis. 
Stage IIIA (G1 or G2 T1 M1): Any grade intra-compartmental lesion with regional nodal or 
distant metastasis. 
Stage IIIB (G1 or G2 T2 M1): Any grade extra-compartmental lesion with metastasis. 
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HISTORY OF LIMB SALVAGE SURGERY AND CUSTOM MADE PROSTHESIS 
Amputation was the traditional treatment for osteosarcomsEiselberg in 1897 and 
Klapp in 1900 are probably the first people to perform limb salvage surgery and used bone 
grafts to reconstruct the defects.  Lexter introduced the concept of using allografts in tumour 
surgeries.  The concept of resection arthrodesis was introduced by Phemister for lesions 
above the knee and this technique was further refined by Merle D‟ Aubigne and Dejouany.  
Till the 1960s the limb salvage surgery for bone tumours was restricted to benign and 
lower grade tumours. The development of newer reconstructive techniques including internal 
fixation led to the cautious use of limb salvage surgeries in high grade sarcomas.
6
 
In the 1970s the improvements in imaging techniques ( CT scans ) and use of 
effective chemotherapeutic agents led to great advances in the limb salvage surgeries. 
Musculoskeletal Tumour Society (MSTS) was formed in this decade and met for the first 
time in 1979.
6 
In the 1980s there were tremendous advances in orthopaedic oncology. Surgical 
staging system was developed, surgical margins were defined and International Society on 
Limb Salvage (ISOLS) was formed in 1981.  In the ISOLS meet in 1981 they reported a local 
recurrence rate of 18% and reconstructive failures in 15% and the second symposium held in 
1983 in Vienna reported a local recurrence of 11% and reconstructive failures in 10%. The 
third meet held at Orlando reported a further declinein local recurrence (7%) and 
reconstructive failures (5%).
6 
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PROXIMAL TIBIAL OSTEOSARCOMAS 
Over the past 25 years the concept of limb salvage surgery has grown dramatically. 
Adriamycin- and methotrexate based chemotherapy which was introduced in the 1970s at 
Memorial–Sloan Kettering, New York University, and the Children‟s Hospital of 
Philadelphia made a huge impact in the prognosis and management of patients with bone 
sarcomas. Pioneering work by surgeons such as Ralph Marcove, Kenneth Francis, andHugh 
Watts led to the development of the techniques of limb salvage surgery.  
 Nowadays 90–95% of patients with extremitysarcomas who are being treated 
at centres specializingin musculoskeletal oncology are undergoing limb salvage surgery 
successfully. Advances in several fields have brought about this dramatic change. The 
following advances are the important ones among them. 
1. Tumour biology and natural history are better understood.  
2. There exists an effective induction chemotherapy with which even borderline cases can be 
salvaged.  
3. Advancements in surgical techniques have brought about better functional outcomes. Even 
limbs in which the vessels have been involved can be salvaged with vascular grafts. 
4. Better appreciation of biomechanics of the musculoskeletal system has led to better 
designing of the prosthesis and better outcomes functionally.  
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5.  Novel materials are being used in the manufacturing of prosthesis due to advances in 
material engineering.  
6.  Prosthesis has been developed for virtually every site in the extremity which has been 
affected by bony tumours.
10
 
 However when considering a limb salvage surgery instead of an amputation certain 
factors have to be kept in mind 
1) There should not be an increased risk to the patient‟s life because of the procedure.  
2) Functional result should be better. 
3) Complication rate must be acceptably low.  
4) Patient and attenders must be fully informed about the procedure, the complications and 
the rehabilitation process.
9
 
 
Several technical issues have to be addressed for the successful outcome of a limb salvage 
surgery.  
a. Key neurovascular structures must be identified and preserved. 
b. Oncological safe margins must be obtained, and preservation of a limb must never 
take priority over thesurvival of the patient. Meticulous surgical technique is 
necessary for achieving a safe margin 
c. Reconstruction of the axial skeleton must be done with appropriate prosthesis 
d. Restoration of good soft-tissue cover isnecessary for good prosthesis function and 
life.
10
 
 
Patient selection for limb salvage surgeries 
The introduction of effective chemotherapeutic agents for osteosarcoma has expanded 
the scope of limb salvage surgery. But the increased survival rates have now placed greater 
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importance on the functional outcome and the prosthesis survival. Today reconstruction has 
to take into account the functional, cosmetic and also the psychological needs of the patient.
10
 
The most important factors that decide about decision to perform a limb salvage 
surgery successfully are location of the tumour and the involvement of neurovascular 
structures.  
Picci et al. listed 6 anatomical sites where providing sufficient margins for resection is 
a problem.
11
 
1. Popliteal space. 
2. Joint structures. 
3. Medullary canal. 
4. Soft tissue involvement. 
5. Venous thrombi. 
6. Sites of periosteal reaction. 
However with the use of preoperative chemotherapy many patients who are 
borderline candidates for limb salvage surgery upfront may ultimately become candidates for 
limb salvage surgery. The patient should always be re-evaluated after the completionof the 
chemotherapy and only then the final decision to proceed or not to proceed with the limb 
salvage surgery must be taken.  
The proximal tibial bony sarcomas are a challenging group of tumours in the 
perspective of limb salvage. Surgical approach to these tumours is difficult, anatomical 
constraints and inadequate soft tissue cover make providing adequate margins and 
reconstruction at this site challenging. Providing a good functional outcome with 
reconstruction of the extensor mechanism is an important aspect of the reconstruction and 
rehabilitation of this subgroup of patient.   
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ANATOMICAL CONSIDERATIONS IN THE PROXIMAL TIBIAL SARCOMAS
12 
A. Popliteal artery trifurcation. 
Thepopliteal trifurcation is actually a combination of two successive bifurcations. 
First the anterior tibial arises from the popliteal artery at the lower border of the popliteus.The 
popliteal artery continues as the tibioperoneal trunk and then bifurcates into peroneal artery 
and the posterior tibial artery. It may be necessary to ligate the anterior tibial artery to provide 
adequate soft tissue clearance. The popliteus muscle on the posterior surface of the tibia 
provides a barrier to the posterior soft tissue extension from the tibia and protects the 
popliteal artery and its branches.
12
 
 
B. Tibiofibular joint. 
Tumours of the proximal tibia have a high incidence of involvement of the tissues of 
the proximal tibiofibular joint. An en-bloc resection of this joint is usually necessary to 
provide adequate margin, especially for high grade sarcomas.
12 
 
C. Knee joint. 
The knee joint is not usually directly involved by the tumours of the proximal tibia. 
This can occur if there has been a fracture or contamination due to a ill performed biopsy 
procedure. Hemarthrosis suggests intra-articular extension of the disease. MRI of the knee 
joint provides the most accurate assessment of the knee joint involvement. If knee joint 
involvement is suspected an extra-articular resection has to be planned.
12 
 
D. Extensor mechanism. 
The reconstruction of the extensor mechanism by reattaching the patellar tendon is a 
challenging aspect of limb salvage surgery of the proximal tibia. Reconstruction of this 
10 
 
mechanism is necessary for a good function of the lower limb. Various mechanisms of 
reconstruction of the extensor mechanisms have been tried over the years and these will be 
described later.
12 
 
E. Subcutaneous location and less soft tissue coverage.  
The medial aspect of the entire length of the tibia occupies the subcutaneous location. This 
leaves the reconstructed prosthesis in a subcutaneous location and is an important source of 
infection and prosthesis failure. The use of the medial gastrocnemius muscle has led to 
provision of adequate soft tissue cover for reconstruction and reduced the incidence of 
infection, flap necrosis, and secondary infection.
12
The musculotendinous insertion of the 
medial gastrocnemius was divided and it was rotated to cover the prosthesis and the 
reconstructed extensor mechanism and sutured to the underlying patellar tendon and the 
quadriceps muscle.
17
 
 
 
Various options exist for the reconstruction of these tumours  
 
1. Resection arthrodesis. 
Prior to the 1970s this was the main method of reconstruction. It had the advantages 
of providing good stability, and a durable reconstruction. But as there was no movement at 
the reconstructed limb as the knee joint was resected and as the result the quality of life was 
poor. Nowadays due to adequate preservation of soft tissue as a result of effective 
chemotherapy and use of medial gastrocnemius for soft tissue cover this method is rarely 
followed.
10 
 
11 
 
 
Fig 1. Intraoperative photograph of resection arthrodesis using dual fibular reconstruction 
with an intramedullary rod fixation following resection of the distal femur, a technique 
popularized by Dr William F. Enneking during 1970s.
10 
 
 
2. Van Nesrotationoplasty. 
This procedure was first described by Borggreve in 1930, but later Van Nes 
popularized it. Here the lower limb is rotated by 180
0 
by knee arthrodesis after resection of 
the tumour, such that at skeletal maturity the ankle joint of the short limb should be at the 
level of the contralateral limb knee joint. The foot acts like the residual tibia in a below knee 
amputation. The functional outcome of Van Nesrotationoplasty is significanty better and also 
needs less energy expenditure compared to the use of an above knee prosthesis. 
Some disadvantages with this procedure are the failure to achieve sufficient rotation 
during the procedure, subsequent derotation due to continued growth of the skeleton and the 
unattractive appearance of the leg in which a reversed foot is used. However there are several 
reports of good patient acceptance and functional outcomes and also acceptable cosmetic 
acceptance by the patients, prosthetists and surgeons.
13,14,15,16
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3. Allograft reconstruction. 
In the 1970s the allograft reconstruction was introduced as a biological solution to the 
problem of restoring a segmental defect of the skeleton. There have been significant advances 
in the techniques of fixation of these prostheses and also in the methods of processing the 
graft so as to preserve the articular cartilage and to lessen the contamination. In spite of these 
advances the use of allografts is not very popular due to the high rates of complication and 
prosthesis failure and also due to the stringent means needed to store these grafts.  These 
grafts are procured according to the established guidelines and stored in a fresh frozen state at 
-80
0
C. Even though the allografts are immunogenic the immune response is reduced by the 
non-vascularity of the graft and also due to the freezing which reduces the antigenicity.  The 
osteoarticular allografts have certain advantages compared to the metallic endoprosthesis. 
They provide articular surface for the adjacent bone and obviate the need for resection of the 
articular surface and the growth plate. They also provide ligaments for joint reconstruction 
and including cruciate ligaments and sites for host tendon reconstruction and provides better 
functional outcome than the metallic endoprosthesis. However these advantages are offset by 
significant complications.Early complications are infection,non-union and joint instability, 
and late complications are instability and allograft fracture.The overall complication rate is 
more than 50%,which includes an infection rate of 30%. As a reason this is being done at few 
centres nowadays. This a good option in young patients who are expected to grow and 
develop substantial limb length discrepancies.  
13 
 
 
Fig 2. Allograft reconstruction of a proximal tibial tumour.
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4. Metallic endoprosthetic reconstruction. 
 Reconstruction of the proximal tibial tumours by endoprosthesis has been a highly 
successful procedure. They are either custom made prosthesis or else modular prosthesis. 
They are made of different alloys, but currently titanium alloy is the preferred one. The 
custom made prosthesis is relatively less expensive than the modular ones. The modular ones 
have the advantage of deciding on table for reconstruction depending upon the amount of 
bone resected. Whereas the custom made prosthesis are prefabricated and is subject to the 
variations in the tumour size and extent changes during therapy. Bone cement that is 
polymethlymethacrylate is usually used to fix this prosthesis. A press-fit porous stem can also 
be used instead of using bone cement. In a retrospective study of 1001 custom made 
prosthesis (which included 493 distal 
14 
 
femoral, 263 proximal femoral and 245 proximal tibial prostheses) aseptic loosening was 
shown to be the principal mode of failure of the implants.
19
 Use of cemented stem allows 
instant fixation which will allow early rehabilitation and mobilization.  
 Improvements in the prosthesis design have also led to the improvements in prosthesis 
survival. In a study by Myers comparing the fixed hinge prosthesis and the rotating hinge 
prosthesis they found risk of revision for any reason in
 
the fixed-hinge group was 32% at five 
years, 61% at ten years
 
and 75% at 15 and 20 years, and in the rotating-hinge group
 
12% at 
five years, 25% at 10 years and 30% at 15 years. The cemented, rotating hinge 
design
 
currently offers the best chance of long-term survival of the
 
prosthesis.
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Expandable prosthesis is a novel innovation which is very helpful in for replacement 
in skeletally immature patients. In most of the commonly used expanding prosthesis a 
surgical procedure is usually required for the subsequent expansions. A novel type of 
expanding prosthesis called the Stanmore expandable prosthesis (Stanmore Implants, 
Stanmore Middlesex, United Kingdom) uses a noninvasive technique for the prosthesis 
expansion. When the patient with the expandable prosthesis is placed at the centre of a 
rotating electromagnetic field the poles of the magnet within expandable segment of the 
prosthesis are captured, causing it to rotate. The external field rotates slowly at a fixed speed 
causing the implant to expand at a rate of 0.23mm per minute (1mm every 4min).  
 
5. Allograft prosthetic composite. 
 This prosthesis is a transitional step in between the allografts and the metallic 
endoprosthesis. This was introduced when they found out that the complication rates of the 
allografts are significantly high. They provide the advantages of biological reconstruction 
leading to better functional outcomes and also provide the advantage of immediate stability 
15 
 
of the endoprosthesis. However results have shown that this prosthesis also carries the high 
complication rates associated with the allografts. 
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TECHNIQUES FOR REPAIR OF THE EXTENSOR MECHANISM 
Various techniques have been described in the literature for reconstruction of the extensor 
mechanism at the knee joint. The degree of surgical resection and also the type of prosthesis 
used for reconstruction influence the choice of extensor mechanism reconstruction. No 
randomised trials exist to compare the various methods of extensor mechanism 
reconstruction. The reconstruction options available according to the prosthesis used are 
described briefly below.  
A. Classic endoprosthesis 
Endoprosthesis are a popular means of reconstruction. The main problem with the use of the 
endoprosthesis is the need to attach the patellar tendon to the metal prosthesis. Various 
techniques have been described to overcome this problem.
22 
(a) Direct Fixation: Horowitz et al
23 
presented a series of 16 patients and in 10 patients the 
reconstruction of the extensor mechanism was done by coronally splitting the patella and 
quadriceps tendon and the remnant patella was directly attached to a porous area on the 
anterior surface of the prosthesis. Functional assessment of 6 of these patients revealed an 
extensor lag of less than 20 
0 
in 4 of these patients. However the direct fixation is associated 
with a high rate of complications and the 8 year follow up of this series revealed that 60% of 
these patients had revision or amputation as a result of the complications.  
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(b) Synthetic soft tissue augments: Many studies have reported the use of textile implants 
such as Dacron tapes, Trevira tube to fix the patellar ligament 
remnant to the prosthesis. 
24, 25
 
The Trevira tube was introduced for extensor mechanism 
reconstruction by Goshegeret al.
26
 „Ligament 
Advancement Reinforcement System (LARS®)‟ which is 
essentially a polyester ligament used to repair the defect in the 
patellar ligament and is secured to the prosthesis at the level of tibial 
tuberosity and also distally at the level of the prosthesis and tibial 
end interface.
27
 Excellent or good functional results were achieved 
in 59% of the patients but ligament failure was seen in 23% (5 
patients).  
 
 
Fig 3. Modular endoprosthetic system Munich-Luebeck, EskaOrthodynamics GmbH,  
uebeck, Germany with the tibial fixation device for the double-layered Trevira cord
24 
 
(c) ‘Biological’ augmentation with or withoutsynthetic materials 
Bickels tried to overcome the lack of healing of the attachment of the extensor apparatus by 
doing a biological fixation.
25 
He used a Dacron® tape to secure the patellar tendon to the 
prosthesis.  He used autologous bone graft to pack the patellar tendon and prosthesis interface 
and covered it with medial gastrocnemius muscle flap. This provided certain advantages: 
immediate mechanical fixation, biological reinforcement to the extensor mechanism, and 
vascularised tissue coverage to minimise infection and facilitate healing. 
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The biological reinforcement done undergoes osseointegration to the underlying porous-
coated surface of the endoprosthesis. At 12 weeks a layered tendon – fibrocartilage – bone 
interface can be seen which resembles a normal tendon insertion. Quality of repair was also 
robust with few patients requiring secondary procedures for reinforcement.  
Kotz and Coombs
22
 reported the use of pedicled fibular graft for attachment of the patellar 
tendon and reconstruction with an endoprosthesis. This provides an advantage of doing a 
biological reconstruction without the use of synthetic material. The fibular graft was based on 
the peroneal vessels and attached to the tibial mid-shaft using screws and its proximal end 
was attached to the patellar tendon.  
 
B. Allograft–endoprosthesis composites 
Though theoretically the composite prosthesis are an attractive option, the high rates of 
failure of the allograft and subsequent failure of the extensor mechanism is discouraging. 
This method of reconstruction is also plagued by a high rate of infection. Donato reported an 
infection rate of 25%.
22
 
 
C. Biologic reconstruction 
Allograft allows direct attachment of the tendons and the ligaments to provide good 
functional outcome. Host patellar tendon is directly attached to the allograft. This can be 
reinforced with muscle flap to minimise the chances of infection and helps in healing. 
Excellent functional outcomes have been reported. In a case series of 34 cases of proximal 
tibial reconstruction using allograft by Ayerzaet al.
22
 they found that the reconstructed tendon 
was stable in all patients at a mean follow up of 52 months. 24 patients had no extensor lag 
and the remaining 10 had a mean lag of 6.5 
0 
. However this technique has a very high 
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complication rate. Clohisy et al reported that 15 of the 16 allografts for the proximal tibia had 
complications and 7 required removal.
22 
 
Muscle Flaps 
The muscle flaps provide the soft tissue coverage for the prosthesis. This reduces the risk of 
infection, facilitates healing and also provides a mechanism for reconstruction of the extensor 
mechanism. Muscle flaps, in particular the pedicled gastrocnemius flap has been very 
popular. This was first used by Dubousset et al. This can be usedas  a muscle or a 
myocutaneous unit. He described two techniques. The first one in which the patellar tendon 
was intact the medial gastrocnemius was transposed anteriorly and sutured to the tendon. 
Here the muscle is not divided at either the proximal or the distal end. In a situation where the 
patellar tendon is deficient the medial gastrocnemius was divided at its distal end and swung 
anteriorly and fixed to the underlying fibula and attached to the patellar tendon.
22
Malawer 
described a technique in which the medial gastrocnemius was rotated over the defect and 
sutured to the borders of the anterior muscles providing a soft tissue cover over the 
prosthesis.
28 
Other flaps described are a combination of gastrocnemius flap and the 
semitendinosus tendon autograft, sartorius, biceps femoris, semitendinosus and 
latissimusdorsi muscle flap.  
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MATERIALS AND METHODS 
Forty one proximal tibialosteosarcoma patients underwent limbsalvage in cancer institute 
between 2001 and 2011.The case records of these patients were reviewed and followed up for 
Quality of life assessment  after limb salvage surgery. 
 
EVALUATION 
Patients suspected of having bone sarcoma were evaluated with X-ray and MRI of the local 
affected part. Metastatic work up was done with Chest X-Ray, CT Chest and Tc99 bone 
scintigraphy. The outside slides and paraffin blocks were procured for patients who had 
undergone biopsy outside. Jamshidi needle biopsy was done at the institute for patients who 
didn‟t have a biopsy done outside.  
 
Tumours are staged according to the 7
th
 edition of the AJCC cancer staging manual
29 
Primary tumour (T) 
TX – Primary tumour cannot be assessed 
T0 – No evidence of primary tumour 
T1- Tumour 8 cm or less in greatest dimension 
T2- Tumour more than 8 cm in the greatest dimension 
T3- Discontinuous tumours in the primary bone site 
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Regional lymph nodes (N) 
NX – Regional lymph nodes cannot be assessed 
N0 – No regional lymph nodal metastasis 
N1 – Regional lymph nodal metastasis 
 
Distant metastasis (M) 
M0 – No distant metastasis 
M1a – Lung metastasis 
M1b – Metastasis to other distant sites 
 
Histological grade (G) 
GX – Grade cannot be assessed 
G1 – Well differentiated – low grade 
G2 – Moderately differentiated – low grade 
G3 – Poorly differentiated 
G4 – Undifferentiated 
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STAGE GROUPING 
STAGE T N M G 
IA T1 N0 M0 G1, G2, GX 
IB T2 N0 M0 G1, G2, GX 
T3 N0 M0 G1, G2, GX 
IIA T1 N0 M0 G3, G4 
IIB T2 N0 M0 G3, G4 
III T3 N0 M0 G3, G4 
IVA Any T N0 M1a Any G 
IVB Any T N1 Any M Any G 
Any T Any N M1b Any G 
 
NEO-ADJUVANT CHEMOTHERAPY 
Neoadjuvant chemotherapy with ifosphamide, adriamycin and cisplatin were given for two 
cycles and the response to chemotherapy was assessed clinically and if necessary radiological 
with MRI. If the patient was found to be a candidate for limb salvage then a scanogram of the 
affected limb was taken and depending on the dimension of the tumour, the bone scan length 
of the lesion and the dimensions of the remaining bone the custom made prosthesis design 
was prepared and ordered for fabrication.  
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Fig 4. Custom made megaprosthesis made of titanium alloy with the grooves for insertion of 
the prolene mesh 
SURGERY 
Surgery is usually performed after 3 to 4 cycles of neo-adjuvant chemotherapy, depending on 
the response to the neo-adjuvant therapy. Repeat imaging is done for reassessment of the 
borderline resectable tumours. Limb salvage surgery is done with custom made mega-
prosthesis.                                                                                                        
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Surgicalprinciples:                                                                                                                                                         
Adhering to the surgical principles of limb salvage and maintaining thorough aseptic 
precautions at each phase of the surgery isthe key for the successful outcomes and avoiding 
preventable complications. It includes thorough pre-surgical scrub with antiseptic solution the 
day before and on the day of surgery and after induction of anaesthesia.                                                                                                                                           
Incision:                                                                                                                                                                              
Incision is placed on the medial aspect starting at the lower end of the femur and extended 
across the knee joint to the middle or lower third of the leg. Incision should include the 
previous biopsy scar. Thick fasciocutaneous flaps are raised                                                                
Popliteal vessel dissection :                                                                                                                                                                                                  
Early popliteal  exploration is the key to assess the resectabilty of the tumor.                                                                                                                                                                                                                                                                                                    
Popliteal space and trifurcation of the popliteal artery is exposed by dissection. Care should 
be taken to preserve the vascular supplyto the medial gastrocnemius which is by the medial 
sural artery which goes in a posteromedial direction to the geniculate artery. Further vascular 
dissection is done by and dividing the medial gastrocnemius insertion and splitting the soleus 
muscle.                                                                                                                                   
Knee joint exposure:                                                                                                                                                                          
The capsule is incised circumferentially 1 cm away from the tibia and the patellar tendon. 
The cruciate ligaments are visually exposed and transected and the knee joint is opened.  
 
Peroneal nerve exposure and tibiofibular joint resection:                                                                                         
Lateral fasciocutaneous flap is raised to expose the proximal fibula and the peroneal 
nerve.The tibio-fibular joint is resected en-bloc along with the tumour.                                                                                                                                                                                                                                                                                   
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Bone cuts:                                                                                                                                                                                                
Distally tibia is transected 3 to 4 cm from the bone scan uptake margin and proximally 
articular plate of femur is transected and the specimen is removed enbloc.                                                                                                       
Fixation of prosthesis:                                                                                                                                                  
Cut ends of the bone are reamed with reamer to accommodate the prosthesis. Bone cement 
(PMMC) is used to fix up the tibial prosthesis in position after checking the alignment.    
 
Fig 5. Fixing the prosthesis with bone cement after ensuring correct alignment 
Soft tissue and Extensor reconstruction:                                                                                                                    
Extensor mechanism is reconstructed using prolene mesh anchored to the prosthesis and the 
patellar ligament using non absorbable suture material prolene. Medial gastrocnemius is 
mobilized to provide coverage for the prosthesis and mesh and sutured to the muscles in the 
anterior compartment.                                                                                                                                                
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Fig 6. Fixing the prolene mesh to the prosthesis  
 
Fig 7. Fixing the prolene mesh to the distal end of the patellar tendon 
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Fig 8. Medial gastrocnemius muscle flap used to wrap around the prosthesis and the 
reconstructed extensor mechanism 
Wound closure:                                                                                                                                                                            
After ensuring complete haemostasis, suction drains are placed and majority of the wounds 
are closed primarily and some cases required skin grafting  to achieve closure of the wound.          
Rehabilitation 
Patient‟s knee was kept extended to allow the reconstructed extensor mechanism to heal. 
Static quadriceps exercises are begun on day 7, non-weight bearing mobilization is begun at 2 
to 3 weeks, weight bearing mobilization is begun at 4-6 weeks and full weight bearing is 
begun at 6-8 weeks. All the rehabilitation is done under the supervision by our 
physiotherapists.                                                                                                      
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FOLLOW UP 
Patients after completion of treatment were followed up according to the institute protocol. 
Monthly in first year, two monthly in the second year, three monthly in the third year, six 
monthly in the fourth and fifth year and then annually. Every visit includes clinical 
examination, chest x-ray, physiotherapy. Quality of life assessment and extensor lag were 
measured after 6 months of the procedure. Further investigation were done as clinical 
symptoms and sign warranted. 
Extensor lag measurement: 
To measure the extensor lag the patient was put in a high sitting posture and using a 
goniometer the range of movements and the lag in extension from full extension was 
measured.  
 
Fig 9.Measurement of the extensor lag using a goniometer.  
 
COMPLICATIONS AND ITS MANAGEMENT 
Patients after limbsalvage surgery face with varieties of complication and they were managed 
appropriately. Marginal skin necrosis was managed mostly by conservative treatment rarely 
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some required debridement and secondary suturing, skin grafting or local flaps. Major 
complications were approached with redoprosthesis for prosthesis fracture, prosthesis 
removal or amputation for prosthesis infection, amputation for local recurrence and 
metastectomy for resectable lung metastasis in a patient with good performance status and 
adequate disease free survival.  
 
ASSESSMENT OF THE QUALITY OF LIFE AND FUNCTION OUTCOME 
Functional outcome assessment was done using the musculoskeletal tumour society scoring 
system (MSTS)
30
  and Quality of life by Cancer Institute Quality of life Questionnaire 
Version II
31
.                                                                     
 Scoring system – International society of limb salvage 
SCORE PAIN FUNCTION EMOTIONAL 
ACCEPTANCE 
SUPPORTS WALKING 
ABILITY 
GAIT 
5 None No Restriction Enthuse None Unlimited Normal 
4 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate 
3 Moderate Restriction in 
recreational 
activities 
Satisfied Brace Limited Minor 
cosmetic 
2 Intermediate Intermediate Intermediate Intermediate Intermediate Intermediate 
1 Moderate Partial disability Accepts One cane or 
crutch 
Household Major 
cosmetic, 
minor 
handicap 
0 Severe Total disability Dislikes Two canes or 
crutches 
Unable to 
walk unaided 
Major 
cosmetic, 
minor 
handicap 
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Cancer Institute QOL questionnaire
31
 consisted of 42 variables and the maximum score was 
180. Higher the score better the quality of life.  The interpretation of the QOL II version is as 
follows:  
1. <99 – Significantly poor 
2. 99-117 – Below average 
3. 118-146 – Average 
4. 147 – 165 – Above average. 
5. >165 – significantly high 
STATISTICAL ANALYSIS 
Statistical analysis was done by SPSS 17 (SPSS software Inc USA). Extensor lag and quality 
of life assessment were analysed by T –test. 
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RESULTS 
41 consecutive patients who underwent limb salvage surgery for proximal tibial 
osteosarcomas from 2001 to 2011 were analysed.  
Mean age of the patients was 17.7 years (range 9-35 years). There were 15 patients with age 
more than 18 years and 26 patients with age up to 18 years.  
29 patients (70.7%) of the patients were male and 12 patients (29.3%) were females.  
J needle biopsy was used for the diagnosis in 32 patients (78%) and open biopsy was 
performed in 9 patients (22%). Of note, no open biopsies were performed in our institute. All 
of the 9 open biopsies were done outside and the slides were reviewed here.  
Preoperative biopsy was the follows 
Histiology Frequency 
Classical osteosarcoma high grade 19 
Chondroblastic osteosarcoma 8 
Pleomorphic sarcoma 11 
Fibroblastic osterosarcoma 1 
Giant cell tumour of bone 1 
Chondrosarcoma 1 
 
The average bone scan length was 13.5 cms and 30 patients had bone scan length of up to 15 
cms and 11 patients had bone scan length more than 15 cms.  
CT chest done upfront showed nodules in the chest in 4 patients. Among these patients 3 had 
solitary pleural based nodule and 1 patient has 2 nodules. However only one patient among 
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the three with solitary nodule in the chest developed lung metastases after limb salvage with a 
DFS of 20.2 months and he underwent metastectomy twice. His overall survival was 70.1 
months.  
Neoadjuvant chemotherapy was given in all but 2 patients. These two patients had a 
preoperative diagnosis of giant cell tumour of the bone and chondrosarcoma respectively. 32 
patients received either 3 or 4 cycles of neoadjuvant chemotherapy. 7 patients received either 
5 or 6 cycles of neoadjuvant chemotherapy.  
16 patients underwent reconstruction with endoprosthesis and myoplasty (gastrocnemius 
muscle flap) and 25 patients underwent reconstruction with mesh-myoplasty (using prolene 
mesh for reconstruction of the extensor mechanism). 31 patients had resection of the fibular 
head and 22 patients had ligation of the anterior tibial artery during resection of the tumour. 6 
patients needed SSG cover during the procedure.  
 
Early complication  
Complications occurring within 30 days of the surgery were considered as early 
complications.  
Early complication Frequency Treatment  
Foot drop 14 Conservative  
Skin necrosis 6 Conservative (2), flap cover (1) and 
secondary suturing (3) 
Foot drop and skin 
necrosis 
1 Conservative  
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Over all 51.2% patients had early minor complications. However about 50% of them were 
foot drops which recovered in most of the patients. None of them had any major complication 
in the early postoperative period for which removal of prosthesis was necessary. 
Complications occurring after 30 postoperative days were considered as late 
complications. Over all 10 patients had late complications (24.4%). 
Late complication Frequency Treatment  
Infection 3 Prosthesis removal (2)  
Amputation (1) 
Fracture prosthesis 2 Redoprosthesis (1)  
Patient was not willing for 
redoprosthesis (1)   
Aseptic loosening 3 Redoprosthesis (3) 
Exposed prosthesis 1 Prosthesis removal 
Fracture of the limb proximal to the 
prosthesis 
1 Open reduction and internal fixation  
 
Post-operative histopathology 
Histology Frequency  
Classical osteosarcoma 23 
Chondroblastic osteosarcoma 9 
Pleomorphic sarcoma  1 
No residual tumour 7 
Giant cell tumour rich osteosarcoma 1 
 
33 
 
Tumour necrosis: 
Percentage of necrosis in the post-operative specimen was examined 
Percentage of necrosis Frequency 
>90
0 
9 (22%) 
0
0
 to 90
0 
32 (78%) 
 
Recurrence: 
10 patients (24.4%) had recurrence on followup.  
Site of recurrence Frequency 
Local 1 
Distant 8 
Local and distant 1 
 
Overall only 2 patients (4.8%) had local recurrence and 9 patients (21.95%) had lung 
metastasis. The patient with both local and distant recurrence was offered only supportive 
care. The patient with only local recurrence defaulted for evaluation. Of the 8 patients with 
only distant metastasis 6 were offered supportive care (due to multiple bilateral 
metastasis)and 1 patient underwent metastectomy twice and had chemotherapy. The other 
patientunderwent metastectomyonce.  
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Survival analysis was done using SPSS 17.0 version and Kaplan Meyers analysis. 
5 years overall survival and disease free survival were 85.5% and 70.6% respectively. In both 
the overall survival and the disease free survival the events occurred during the first 2 years.  
The mean overall survival was 38 months and mean disease free survival was 34 months.  
 
 
 
 
 
 
 
Factors like age of the patient, type of biopsy, bone scan length of the lesion, number of 
preoperative chemotherapy cycles, type of surgery and amount of necrosis in the post-
operative specimen were evaluated for impact on survival.  
Among these there was a statistically significant difference in survival only in patients 
receiving 3 to 4 cycles of neo-adjuvant chemotherapy versus those receiving 5 to 6 cycles of 
neo-adjuvant chemotherapy with the 5 year overall survival being 94.1% versus 68.6% 
respectively  
(p= 0.045) 
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S.No Variable 5 year overall survival 
in % 
p value 
1.  Age upto 18 years 81.4 NS 
 Age > 18 years 93.3  
2.  Bone scan length upto 15 cms 85.7 NS 
 Bone scan length >15 cms 90.9  
3.  J needle biopsy 84.3 NS 
 Open biopsy 87.5  
4 3 to 4 cycles pre op chemo  94.1 0.045 
 5 to 6 cycles pre op chemo 68.6  
5 Myoplasty 86.7 0.885 
 Meshmyoplasty 84.7  
6 Necrosis upto 90% 84.6 NS 
 Necrosis >90% 87.5  
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Disease free survival: 
Similarly these factors were analysed for any influence on the disease free survival. 
S.No Variable 5 year Disease free 
survival in% 
p value 
1.  Age upto 18 years 64.8 NS 
 Age > 18 years 80  
2.  Bone scan length upto 15 cms 64.3 NS 
 Bone scan length >15 cms 90.9  
3.  J needle biopsy 75.5 NS 
 Open biopsy 53.3  
4 3 to 4 cycles pre op chemo  76.9 NS 
 5 to 6 cycles pre op chemo 53.6  
5 Myoplasty 80.8 NS 
 Meshmyoplasty 62  
6 Necrosis upto 90% 68.5 NS 
 Necrosis >90% 77.8  
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Prosthesis survival: 
 The mean prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). The 5 
year prosthesis survival was 86.5%. All of the prosthesis failures occurred in the first 3 years. 
Prosthesis survival was analysed with respect to bone scan length, type of surgery (myoplasty 
versus meshmyoplasty), depending on the type of the biopsy and whether the patient received 
3 to 4 or 5 to 6 cycles of pre-operative chemo.  
 
S.No Variable 5 year prosthesis 
survival in% 
p value 
1.  Bone scan length upto 15 cms 89.8 NS 
 Bone scan length >15 cms 85.7  
2.  J needle biopsy 88.7 NS 
 Open biopsy 77.8  
3.  3 to 4 cycles pre op chemo  89.3 NS 
 5 to 6 cycles pre op chemo 71.4  
4 Myoplasty 93.8 NS 
 Meshmyoplasty 79.9  
 
There was no statistically significant difference in the prosthesis survival between the cases 
that underwent myoplasty and meshmyoplasty. 
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Quality of life assessment: 
Quality of life assessment was done based on the Cancer Institute QOL questionnaire II for 
cancer patients
31
and the MSTS scoring system
30
 was used for the functional outcome.  
Of the 41 patients 4 of the patients were lost to follow-up and were not available for QOL 
assessment. 2 patients died and 2 patients had their prosthesis removed before the time of 
QOL assessment. So QOL was done for 33 patients and among these 24 had undergone 
meshmyoplasty and 9 had undergone myoplasty. Following are the results of the analysis.  
 
QOL Variable Myoplasty Mesh-myoplasty p Value using T test 
QOL total 148.89 144.17 0.197 
General  well being 25.78 23.71 0.075 
Physical well being 37.11 36.0 0.139 
Psychological well 
being 
23.89 24.71 0.627 
Interpersonal 
relationship 
15.44 14.63 0.207 
Sexual and personal 
ability 
4.78 4.50 0.713 
Cognitive well being 11.00 11.21 0.642 
Optimism and belief 7.67 7.50 0.599 
Economical well 
being 
8.78 8.67 0.875 
Information support 7.56 6.46 0.035 
Patient physician 
relationship 
4.00 3.88 0.414 
Body image 2.89 2.92 0.937 
 
39 
 
QOL analysis between the two type of surgeries i.e. myoplasty and mesh-myoplasty did not 
show any statistically significant outcomes in the overall quality of life. However  theover all 
QOL was slightly better in the analysis done for information support. Information support 
was concerned with the amount of information the patient expected and the amount of 
information the patients were able to get from the doctors.  
 
Functional outcome was assessed using the MSTS scoring system
30 
A total of 6 factors were analysed and the following are the results. 
MSTS variable Myoplasty (mean) Mesh-myoplasty 
(mean) 
p Value using T test 
PAIN 4.78 4.67 0.599 
FUNCTION 3.56 3.33 0.479 
EMOTIONAL 
ACCEPTANCE 
2.89 3.50 0.031 
SUPPORTS 4.44 4.54 0.748 
WALKING ABILITY 3.56 3.29 0.397 
GAIT 3.11 3.04 0.805 
TOTAL 22.33 22.38 0.964 
 
 
This shows that the overall functional outcome between the patients undergoing myoplasty 
and mesh-myoplasty was similar. However when the patients were analysed based on the 
emotional acceptance of the patients, the patients undergoing mesh-myoplasty showed a 
statistically better outcome (p=0.031) than the group undergoing myoplasty. 
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EXTENSOR LAG ANALYSIS 
Extensor lag was measured for 32 patients (8 with myoplasty and 24 with 
meshmyoplasty). 4 patients were lost to follow up, 3 patients were dead and 2 patients had 
their prosthesis removed due to infection prior to the time when the extensor lag was 
measured.  
The mean extensor lag in the patients undergoing myoplasty was 68.13
0 
and the mean 
extensor lag in the patients undergoing mesh-myoplasty was 36.66
0 
and the difference was 
statistically significant (p=0.004).  
 
Type of surgery 0
0 
1
0
 – 200 210 – 500 510 – 700 >700 
Myoplasty 0 0 1 3 4 
Mesh-myoplasty 2 5 13 1 3 
 
None of the patients in the myoplasty arm had an extensor lag of less than 21
0 
. Whereas 2 
patients with mesh-myoplasty had 0
0 
extensor lag. 
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DISCUSSION 
 The management and the outcomes including the survival and the functional 
outcomes of proximal tibial osteosarcomas has changed considerably due to the use of 
chemotherapy, use of advanced imaging technology and refinements of surgical techniques. 
The prosthesis survival also has increased due to use of better quality and designing of 
prosthesis. Endoprosthetic reconstruction is now the preferred method used for reconstruction 
with various methods used for reconstruction of the extensor mechanism which is one of the 
important factors affecting the functional outcomes.  
 In our study we included 41 consecutive cases of proximal tibial osteosarcomas who 
underwent limb salvage surgery at our institute from 2001 to 2011 with a mean follow up of 
38 months. 
 The mean age of the patients was 17.7 years (range 9-35 years). There were 15 
patients with age more than 18 years and 26 patients with age up to 18 years. In the German-
Austrian-Swiss co-operative study group comparison of the overall survival of the patients 
with age of the patients <40 years and >=40 years showed statistically significant difference 
in favour of the group less than 40 yrs of age 
Our study did not show any statistically significant difference in the age group =< 18 years 
and > 18 years. 
Generally many studies have shown that proximal tibial osteosarcomas are a 
favourable sub-site for the sarcomas
19, 32
.  
 The Cooperative German-Austrian-Swiss Osteosarcoma Study Group
32 
in their 
analysis of 1702 cases of osteosarcomas found that the tumours in the proximal tibia had a 
5year and 10 year overall survival of 77.5% and 72.0% respectively, whereas the overall 
survival in the entire group for 5 years and 10 years was 65.3% and 59.8%. 
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 In the Brazilian osteosarcoma treatment group studies III and IV by SérgioPetrilliet 
al
34
, they found that the overall 5 and 10 year survival was 50.1% and 46.7% whereas it was 
60.0% and 56.7% respectively for tumours arising in the proximal tibia 
However in our study we have included only cases which had small volume tumours 
with better prognosis and who have undergone limb salvage surgery where as the other 
studies quoted have included cases with metastasis and also patients who have undergone 
amputation.  
 Various studies have shown that the outcomes with larger tumour volumes have been 
poorer
32, 33
. In our study we used the bone scan length of the tumour to classify them into 2 
categories. They were classified as tumour with bone scan length =<15 cms (30 patients – 
73.2%) and tumours >15 cms (11 patients – 26.8%). We did not find any statistically 
significant difference in the survival in these two subgroups.  
 If patients are having extensive soft tissue component then it is one of the relative 
contraindications to performing limb salvage surgery. Spanier et al. from the University of 
Florida have extensively studied the effect of local extent of the tumour on disease free 
survival and overall survival.
35 
 They studied the effect of the local tumour extent on the disease free survival. They 
included 51 patients with Enneking stage IIB tumours. They classified the tumours into 6 
types depending on the local extent of the tumour.  
E1 – Tumour only touches the periosteum but does not elevate or penetrate it.  
E2 – Tumour touches and elevates the periosteum but does not penetrate it.  
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E3 – Tumour penetrates into the periosteum but does not penetrate through the periosteum. 
E4 – Tumour penetrates through the periosteum with minimum extraperiosteal extension 
without invasion of another structure (like muscle, tendon or ligament) 
E5- Tumour invades one additional structure  
E6 – Tumour invades two or more additional structures.35 
They found that the risk of failure was 5.9 times higher if tumour involed 2 or more 
surrounding tissues compared to the other subgroups.
35
 
  
Study Size of the 
tumour 
OS p Value DFS p Value 
German-Austrian-Swiss group
32 
< one third 72.1% <.0001 61.0% <.0001 
>= one third  58.4% 42.9% 
Bacci et al
33 
based on the tumour 
volume 
=<150 ml    65% NS 
>150 ml  52% 
SérgioPetrilli et al
34  
-tumour 
length 
=<12cms 64.5% <.0001 48.1% .009 
>12 cms 40.5% 30.4% 
Spanier SS, Shuster JJ, Vander 
Griend RA
35 
E1 – E5 82.3%  79.8%  
E6 37.8% 17.6% 
Our study – Bone scan length =<15cms 85.5% NS 64.8% NS 
>15 cms 64.3% 90.9% 
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Chemotherapy  
The use of chemotherapy has brought about a revolution in the outlook of these 
previously lethal tumours. The advantages of giving preoperative chemotherapy include: 
1. Early initiation of the systemic therapy. 
2. Borderline cases for limb salvage can undergo limb salvage surgery following tumour 
shrinkage after chemotherapy. 
3. The response of the tumour to the chemotherapy can be assessed.  
4. Provides time for designing and fabrication of the custom made prosthesis. 
However the disadvantage is that the chemotherapeutic agent has to act against a large 
tumour burden.   
Pediatric oncology group conducted a randomised control trial POG 8651, to compare the 
preoperative chemotherapy versus adjuvant chemotherapy. Of the 100 patients 45 underwent 
preoperative chemotherapy and 55 underwent straight surgery followed by chemotherapy. 
The 5 years DFS for undergoing immediate surgery and preoperative chemotherapy was 65% 
and 61 % (p -.8) and the rate of limb salvage for these groups were 55% and 50% 
respectively. It was concluded that chemotherapy was effective in both the settings
36
. In our 
study 2 patients did not receive a preoperative chemotherapy because the preoperative 
diagnosis for these patients was giant cell tumour of the bone in one case and 
chondrosarcoma in the other case. As the number of cases undergoing immediate surgery was 
very less statistical analysis couldn‟t be done.  
The response to neo-adjuvant chemotherapy has been an important prognostic factor 
for the overall and the disease free survivals. Several centres have developed criteria to 
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evaluate the chemotherapy response. Huvos et al. at MSKCC
37
, Salzer-Kuntschik et al.
38
 ( 
system used by the COSS study group) and Picci et al 
39 
at InstitutiOrthopedico Rizzoli 
independently developed criteria to assess the tumour response to chemotherapy. But as a 
consensus a tumour response >90% is taken as good response and =<90% is taken as poor 
response.  
Using this criterion the chemotherapy response was assessed in our study and 30 
patients (76.92%) were poor responders and 9 (22%) were good responders. 
Response to chemotherapy has been reported by various studies and has been a 
statistically significant predictor of survival
32, 34, 40
. However the update by Bacciet al
33 
did 
not show any statistically significant difference in the outcomes of poor responders to 
chemotherapy compared to the good responders.  
Huvos et al
37 
Salzer-Kuntschik et al.
38
 Picci et al 
39
 
IV No histologic evidence 
of viable tumor 
I No viable tumor cells Good 
response 
90%-99% 
tumor 
necrosis 
III Only scattered foci of 
viable tumor cells 
II Single viable tumor 
cells or cluster <0.5 cm 
Fair response 60%-89% 
tumor 
necrosis 
II Areas of necrosis due to 
chemotherapy with 
areas of viable tumor 
III Viable tumor<10% Poor 
response 
<60% tumor 
necrosis 
I Little or no 
chemotherapy effect 
IV Viable tumor 10% - 
50% 
  
  V Viable tumor>50%   
  VI No effect of 
chemotherapy 
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Response to preoperative chemotherapy and survival outcomes 
Study  Disease free survival p value Overall survival p value 
Good 
responders 
Poor 
responders 
 Good 
responders 
Poor 
responders 
 
COSS study
32 
67.6% 38.6% <.0001 77.8% 73.4% <.0001 
SigbjornSmeland 
et al
40 
89% 53% .004    
Bacci G
33 
62% 51% NS    
Our study 68.5% 77.8% 0.539 87.5% 84.6% 0.521 
 
Even though our study did not reveal a significant difference in the survival of the patients 
with poor response to preoperative chemotherapy compared to the patients with good 
response, the survival curves never met and may be with more number of patients or a longer 
follow up we may be able to appreciate a difference in survival between these subgroups.  
 We also analysed the survival of the patients who had received 3 to 4 cycles of 
preoperative chemotherapy versus those receiving 5 to 6 cycles of preoperative chemo. We 
found that patients receiving 3 to 4 cycles of chemotherapy had a statistically significant 
better overall survival ( 94.1% versus 68.6% with p = .045 ) compared to the patients who 
received 5 to 6 cycles of chemotherapy. 
 We also analysed the survival outcomes with respect to type of surgery (myoplasty 
v/s meshmyoplasty), whether the fibular head was resected or not, whether the anterior tibial 
artery was ligated or not and also depending on the type of biopsy (J needle biopsy versus 
open biopsy). The survival outcomes between the above compared subgroups were not 
different statistically.  
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Recurrences 
There were 10 cases of recurrence in our series. 1 patient had local recurrence, 1 patient had 
both local recurrence and distant metastasis and 8 patients had lung metastasis. The mean 
duration for recurrence or metastasis was 14.97 months (range 4.9 to 26.3 months). The local 
recurrence rate was 4.8% (2 patients) and the distant recurrence rate was 21.95% (9 patients). 
Most of the published series for limb salvage surgery have documented involved margins, 
larger size of the tumour, open biopsy, local response to chemotherapy and low volume 
centres as significant predictors for local recurrence. 
41, 42, 43, 44, 40, 34 
In our study none of the patients had margin positivity and as the number of local recurrences 
was only 2 statistical analyses couldn‟t be done.  
Our local recurrence rates are comparable with the major published series.  
Study Local recurrence rate 
P. Picci et al
41 
7% 
D. Andreou et al
42 
5.6% 
Sigbjorn Smeland
40 
4% 
A. Sérgio Petrilli
34 
10% 
Torbert, Jesse T MD et al
43 
6.8% 
Bacci G et al
44 
6% 
 
12.6% 
Our study 4.8% 
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Prosthesis survival  
 The mean prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). 
The 5 yr prosthesis survival was 86.5%. All of the prosthesis failures occurred in the first 3 
years. Prosthesis survival was analysed with respect to bone scan length, type of surgery 
(myoplasty versus meshmyoplasty), depending on the type of the biopsy and whether the 
patient received 3 to 4 or 5 to 6 cycles of pre-operative chemo. There was no statistically 
significant difference in the above compare subgroups. 
 Our prosthesis survival of 86.5% is comparable to the various studies quoted in the 
literature regarding the prosthesis survival. 
 
 
Study  Proximal tibial Prosthesis survival 
5 years 10 years 
MayilVahananNatarajan et al.
45 
85.5  
Adam J. Schwartz MD et al.
46 
93.8% 86.5% 
G. J. C. Myers
20 
(fixed hinge) 68% 39% 
G. J. C. Myers
20 
(rotating hinge) 88% 75% 
Flint et al.
47 
(fixed hinge) 73%  
Wu et al
48 
(custom prosthesis) 44.4% 22.2% 
Wu et al
48 
(modular prosthesis) 81.4% 65.3% 
Our study (over all) 86.5%  
Our study (myoplasty) 93.5%  
Our study (meshmyoplasty) 79.9%  
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Even though the 5 yr prosthesis survival was better in the myoplasty arm it did not reach 
statistical significance. The 8 year prosthesis survival was 64.3% for the myoplasty arm and 
79.9% for the meshmyoplasty arm. Most of the events have occurred in the first 3 years. 
However we need a longer follow up with the meshmyoplasty arm to clearly tell us about the 
long term outcomes.  
Complications 
 Early complications were taken as the complications occuring within 30 days of the 
surgery. Of the 41 patients 14 patients had a temporary foot drop which recovery in all but 2 
of the patients on followup. 6 patients has mariginal skin necrosis which was managed 
conservatively in 2, by flap cover in 1 and with secondary suturing in 3 patients. 1 patient had 
both foot drop and marginal skin necrosis and was managed conservatively 
 Late complications were taken as those occuring after 30 days of the surgery. In our 
series 10 patients (24.4%) had late complications.  The following were the complication 
breakdown and the treatment given for them.  
Late complication Frequency Treatment  
Infection 3 (7.31%) Prosthesis removal (2)  
Amputation (1) 
Fracture prosthesis 2 (4.87%) Redoprosthesis (1)  
Conservative treatment(1)   
Aseptic loosening 3 (7.31%) Redoprosthesis (3) 
Exposed prosthesis 1 (2.43%) Prosthesis removal 
Fracture of the limb proximal to the 
prosthesis 
1 (2.43%) Open reduction and internal fixation  
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In most of the series reported on proximal tibial prosthesis, infection and aseptic loosening 
has been stated as most common causes for prostesis failure.  
Here we compare the infection rates, asceptic loosening rates and prosthesis loosening rates 
of our study with the other studies stated in literature. 
 
 
Study Infection  Asceptic 
loosening 
Fracture 
prosthesis 
Our study 7.31% 7.31% 4.87% 
 
With gastrocnemius 12% - 3.31% 
(5/151) Without gastrocnemius 36% 
P. S. Unwin et al.
19
 36.58% 19.51% 4% 
Jacob Bickels et al
25
 3.6% - 3.63% 
Myers et al
20 
Fixed hinge  19.5% 46% 1.92% 
Rotating hinge 3% 
Flint MN et al
47 
Uncemented prosthesis 15.9% 0% 4.54% 
Adam J. Schwartz et a.l
46 
5.8% 11.53%  
MayilVahananNatarajan et al.
45 
12%   
Wu CC et al.
48 
15.9%   
Horowitz et al.
23 
37.5%   
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 The major complications in the proximal tibial prosthesis are infection, aseptic 
loosening and fracture of the prosthesis stem. Infections rates have come down with the use 
of adequate soft tissue cover, basically used is the medial gastrocnemius muscle flap.  
Aseptic loosening of the prosthesis is another complication in which the use of prosthesis 
with a rotating hinge has reduced the incidence. Recent reports of using uncemented 
prosthesis have also reported a reduction in the rates of aseptic loosening.  
 So these technical modifications have reduced the complication rates in this 
anatomical site which traditionally has a higher complication rate.  
 
Quality of life assessment  
 QOL was analysed by the Cancer Institute QOL Questionnaire
31 
which is based on 42 
questions and based on that scores are given. Higher the scores better the QOL. 
The score of the patients undergoing myoplasty was 148.89 which is just above the average 
score, and the score of the patient undergoing mesh-myoplasty was 144.17 which is in the 
higher range of average scores. There was no statistically significant difference in the quality 
of life of the patients undergoing myoplasty or mesh-myoplasty.  
 None of the factors subgrouped to denote different aspects of the quality of life 
showed any difference in the two groups except the aspect of information support.  
 Over all the quality of life was satisfactory. 
Functional outcome assessment. 
 Functional outcome was assessed using MSTS scoring system
30
. The mean MSTS 
score was 22.35 (74.5%). It was 22.33 in the patients undergoing myoplasty and 22.38 in the 
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patients undergoing mesh-myoplasty. Comparison of the functional outcome between the two 
groups was not statistically significant. However while analysing the scores concerned with 
„emotional acceptance‟ there was a statistically significant difference in favour of the group 
in which the reconstruction was done using mesh-myoplasty.  
The MSTS score of our series was comparable with those in the other series. 
 
Study  MSTS score 
 77% 
Vijay Titus MS
49
82.1% 
Adam J. Schwartz MD et al.
46
 82% 
Zhang Y.
50 
(tibiofibular joint involved) 70% 
Flint MN et al
47
 75% 
Our study 74.5% 
 
As compared above the functional outcomes of the patients in our series is satisfactory. 
Extensor lag 
 The active extensor lag for the patients undergoing myoplasty was 68.13
0
and for the 
patients undergoing mesh-myoplasty was 38.81
0
. The difference in the outcomes was 
statistically significant in favour of the group undergoing mesh-myoplasty (p=0.004). No 
revision surgeries were done in our surgeries for the repair of the extensor mechanism.  The 
following table compares the outcomes of the extensor lag of our series with that of other 
series. 
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Study Mean Extensor Lag 
Our study (myoplasty) 68.13
0
 
Our study (mesh-myoplasty) 38.81
0 
 30
0 
Adam J. Schwartz MD et al.
46
17.9
0 
Flint MN et al
47
 6
0 
Vijay Titus MS
49
 4
0  
Dominkus M
27 
25
0 
Gosheger G
26 
7.5
0 
Shimose S
51 
26
0 
 
Though the extensor lag in the mesh-myoplasty arm in our series was significantly better than 
the arm which underwent myoplasty alone, it was more than some of the other studies. The 
extensor lag in our series could be further improved by  
1. Considering revision surgery for the extensor mechanism for patients with poor extension.  
2. Extensor mechanism could be augmented with bone grafts, wire cerclage, etc. 
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CONCLUSION 
1. With the use of effective modern chemotherapy osteosarcoma treatment has seen a 
paradigm shift. Excellent survival results are seen in the proximal tibial osteosarcomas in our 
study which is at par with the international studies. Patients receiving 3 to 4 cycles of 
preoperative chemotherapy showed better survival outcome than those receiving 5 to 6 cycles 
of preoperative chemotherapy, thought it was not statistically significant. Good responders to 
preoperative chemotherapy also showed a trend towards better survival though it was not 
statistically significant. 
2. Limb salvage surgery has been very satisfactorily done for the proximal tibial 
osteosarcomas, which is traditionally considered a difficult site to reconstruct.  
3. Prosthesis survival at this site is influenced by a high rate of complications which include 
infection, prosthesis loosening and fracture of the prosthesis. The modifications of the 
surgical techniques and use of flaps for soft tissue cover has significantly reduced these 
complications.  
4. There was no statistically significant difference in the prosthesis survival times of the 
patients undergoing myoplasty versus those undergoing mesh-myoplasty.  
5. The extensor lag was significantly better in the patients undergoing mesh-myoplasty, but 
compared to international studies it was slightly inferior. We may need to consider the use of 
bone grafts augmentation for better bio-integration of the extensor mechanism.  
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ABSTRACT 
 
Limb salvage surgery in osteosarcomas of the upper end of the tibia encompasses 
several challenges. Among those challenges lack of soft tissue cover, higher rates of 
prosthesis failure and difficulty in reconstructing extensor mechanism of the knee joint are 
important.  
Retrospective analysis of 41 consecutive patients undergoing limb salvage surgery for 
proximal tibialosteosarcomas at our institute from 2001 to 2011.16 patients underwent 
reconstruction with endoprosthesis and myoplasty (gastrocnemius muscle flap) and 25 
patients underwent reconstruction with mesh-myoplasty (using prolene mesh for 
reconstruction of the extensor mechanism). The 5 yr overall survival and disease free survival 
was 85.5% and 70.6%. Patients who has 3 to 4 cycles of preoperative chemotherapy had 
significantly better 5 year overall survival then those who received 5 to 6 cycles of 
chemotherapy. (94.1% versus 68.6%). 9 patients (22%) had tumour necrosis >90% and 32 
patients (78%) had tumour necrosis =<90%, but there was no statistically significant 
difference in the overall survivals of these two groups (87.5% versus 84.6%). The mean 
prosthesis survival was 34.5 months ( range 2.3 months to 133.1 months ). The 5 year 
prosthesis survival was 86.5%. Infection (3), aseptic loosening (3) and fracture of the 
prosthesis (2) were the main reasons for prosthesis failure. There was no statistically 
significant difference in the prosthesis survival between the cases that underwent myoplasty 
and meshmyoplasty. 
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Quality of life analysis was done using the Cancer Institute QOL questionnaire II and 
functional outcomes were evaluated with MSTS scoring system (mean score 74.5%). There 
was no statistically significant difference in the quality of life outcomes or functional 
outcomes according to these scoring systems. But the mean extensor lag in the patients 
undergoing myoplasty was 68.13
0 
and the mean extensor lag in the patients undergoing mesh-
myoplasty was 36.66
0 
and the difference was statistically significant (p=0.004). 2 patients 
with meshmyoplasty had 0
0 
extensor lag whereas none of the patients with myoplasty had 0
0 
extensor lag.  
8 patients had lung metastasis, 1 patient had local recurrence and 1 patient had both 
local recurrence and lung metastasis.  
The prosthesis survival and the functional outcomes (MSTS scores) in our series is 
comparable to the other series in literature on endoprosthetic reconstruction for proximal 
tibial osteosarcomas.  
Keywords: Custom made endoprosthesis, proximal tibial osteosarcoma, limb salvage surgery 
 
